
==== Front
Cell Commun Signal
Cell Commun Signal
Cell Communication and Signaling : CCS
1478-811X
BioMed Central London

1812
10.1186/s12964-024-01812-6
Review
Interactions between hedgehog signaling pathway and the complex tumor microenvironment in breast cancer: current knowledge and therapeutic promises
Liu Ruijuan 12
Yu Yang 3
Wang Qingyang 1
Zhao Qianxiang 1
Yao Yan 2
Sun Mengxuan 1
Zhuang Jing 13963676719@163.com

2
Sun Changgang scgdoctor@126.com

24
Qi Yuanfu qiyuanfu@163.com

5
1 https://ror.org/0523y5c19 grid.464402.0 0000 0000 9459 9325 College of First Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, 250014 China
2 grid.461885.6 Department of Oncology, Weifang Traditional Chinese Hospital, Weifang, 261000 China
3 grid.259384.1 0000 0000 8945 4455 Faculty of Chinese Medicine, State Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Macau, 999078 China
4 https://ror.org/02my3bx32 grid.257143.6 0000 0004 1772 1285 College of Traditional Chinese Medicine, Shandong Second Medical University, Weifang, 261000 China
5 https://ror.org/052q26725 grid.479672.9 Department of Oncology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250014 China
9 9 2024
9 9 2024
2024
22 43224 5 2024
31 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Breast cancer ranks as one of the most common malignancies among women, with its prognosis and therapeutic efficacy heavily influenced by factors associated with the tumor cell biology, particularly the tumor microenvironment (TME). The diverse elements of the TME are engaged in dynamic bidirectional signaling interactions with various pathways, which together dictate the growth, invasiveness, and metastatic potential of breast cancer. The Hedgehog (Hh) signaling pathway, first identified in Drosophila, has been established as playing a critical role in human development and disease. Notably, the dysregulation of the Hh pathway is recognized as a major driver in the initiation, progression, and metastasis of breast cancer. Consequently, elucidating the mechanisms by which the Hh pathway interacts with the distinct components of the breast cancer TME is essential for comprehensively evaluating the link between Hh pathway activation and breast cancer risk. This understanding is also imperative for devising novel targeted therapeutic strategies and preventive measures against breast cancer. In this review, we delineate the current understanding of the impact of Hh pathway perturbations on the breast cancer TME, including the intricate and complex network of intersecting signaling cascades. Additionally, we focus on the therapeutic promise and clinical challenges of Hh pathway inhibitors that target the TME, providing insights into their potential clinical utility and the obstacles that must be overcome to harness their full therapeutic potential.

Keywords

Hedgehog signaling pathway
Breast cancer
Tumor microenvironment
Therapeutics
http://dx.doi.org/10.13039/501100007129 Natural Science Foundation of Shandong Province ZR2021LZY015 ZR2021LZY015 Traditional Chinese Medicine Science and Technology Project of Shandong ProvinceZ-2022021 Qingdao Municipal Science and Technology Benefit the People Demonstration Project23-2-8-smjk-1-nsh issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Solid tumors represent a highly complex and heterogeneous ecosystem comprising many cell types, cell states, and extracellular components. The tumor microenvironment (TME) contains a variable fraction of cancer cells, ranging from 5% to almost 100%, with the remainder consisting of other infiltrating and resident host cells, extracellular matrix, and secreted factors [1]. In this ‘nest,’ tumor cells interact with other cell populations by undergoing differentiation, epigenetic changes, dissemination, and immune escape [2]. The reciprocal influence that malignant cells and other cellular populations in the TME exert on each other represents a driving force that actively shapes disease progression and influences treatment outcomes [1, 3]. Therefore, various strategies for reshaping TME have become increasingly crucial for tumor therapy.

To date, the biological complexity coupled with invasion and metastatic cascades has indeed limited the research and investment in potentially valuable novel therapeutic agents [4]. The Hedgehog (Hh) signaling pathway has been recognized as one of the most intensively investigated targets in cancer therapy, playing a critical regulatory role in multiple biological processes ranging from embryo development and tissue patterning to cancer initiation, progression, and metastasis [5]. For example, the Hh pathway is quiescent in the adult mammary gland but reactivated in up to 30% of breast cancer [6, 7]. Aberrant Hh signaling activation may accelerate breast cancer growth and lead to tumor immune tolerance and drug resistance. The interaction between Hh signaling and the TME is intimately involved in these processes, such as tumor growth, tumor immune tolerance, inflammation, and drug resistance [8]. This review aims to review the current understanding of the role and mechanisms of aberrant Hh signaling activation in breast cancer TME and highlight potential therapeutic insights.

Hedgehog pathway in tumors

The Hh signaling pathway is a complex intracellular signaling mechanism associated with the development and progression of various solid malignancies due to sporadic mutations or other mechanisms of constitutive activation. In oncogenesis, the activation of the Hh signaling pathway, which can lead to tumor development, occurs through two primary mechanisms—ligand-dependent (canonical Hh signaling) and ligand-independent (non-canonical Hh signaling)(Fig. 1). Previous studies have extensively documented the two modes of aberrant activation, and in this article, we provide a brief overview of them [5, 9].

Fig. 1 Activation and regulation of Hh pathway in vertebrates. The canonical Hh signaling pathway is initiated by the binding of Hh ligands to the transmembrane protein Ptch, which inhibits the Ptch-dependent suppression of Smoothened SMO, leading to the activation of the Gli signaling pathway. Left panel: In the presence of Hh ligands, the engagement of these ligands—IHh, Shh, or DHh—with the Ptch receptor results in the alleviation of Ptch’s inhibitory effect on Smo. Subsequently, the activated Smo conveys the Hh activation signal into the cytoplasm. Ultimately, the Suppressor of Fused (Sufu) releases Gli proteins from the cytoplasm, enabling their translocation to the nucleus, where they initiate the transcription and expression of their target genes, including Gli1, Gli2, and Gli3. Right panel: In the absence of Hh ligands, Ptch liberates proteins that inhibit Smo activity, thereby preventing Smo activation and shutting down the Hh signaling pathway

The canonical Hh pathway is initiated by the binding of Hh ligands (such as Sonic Hedgehog (Shh), or Indian Hedgehog (IHh), and Desert Hedgehog (DHh)) to their receptor Ptched (Ptch), which relieves Ptch-mediated inhibition of Smoothened (SMO) [10]. Subsequently, the activated SMO translocates to the primary cilium. where it promotes the inhibition and activation of the GLI family of transcription factors (Gli1, Gli2, and Gli3) [11] (Fig. 1). These activated transcription factors then translocate to the nucleus and regulate the expression of a series of target genes involved in various biological processes such as cell proliferation, differentiation, and survival [5, 12, 13]. The non-canonical Hh pathway operates independently of SMO and can participate in cellular signaling through various mechanisms. In this pathway, Hh signaling can directly activate non-SMO-dependent signaling molecules or interact with other signaling pathways such as Transforming growth factor β (TGF-β), Notch, and PI3K/AKT, thereby influencing cellular behavior [14]. The non-canonical Hh pathway plays a role in tissue repair, modulation of the tumor microenvironment, and maintenance of cancer stem cells [15]. Currently, our understanding of the non-canonical Hh signaling pathway and its mechanisms remains incomplete. Indeed, it seems that the non-canonical pathway serves as a backup route that comes into play when the canonical Hh pathway is inactive.

Both signaling events are essential roles in cell fate determination, tissue morphogenesis, and disease development. In cancer, aberrant activation of the canonical Hh pathway is associated with the development of various tumors, such as breast cancer, basal cell carcinoma, medulloblastoma, and certain types of lung cancer [16, 17]. Although the role of the non-canonical Hh pathway in cancer is not as well-defined as the canonical pathway, a reassessment of multiple Hedgehog network members is needed to synthesize an accurate understanding of Hedgehog network functions in a given biological context.

TME factors and conditions that modulate the hh signaling in breast cancer

It is a well-established fact that tumor development and metastasis depend on the two-way interaction between cancer cells and their environment, thereby forming the TME. Solid tumors are surrounded by a complex and dynamic microenvironment involving stromal cells, immune cells, extracellular matrix components, and a specific physical environment. As depicted in Fig. 2, the interplay between Hh signaling and the TME is multifaceted. The Hh ligands secreted by cancer cells, such as Shh, can activate the Hh pathway in both cancer and stromal cells, leading to the upregulation of target genes like Gli1 and CyclinD1, which foster cell proliferation and resistance. Furthermore, Hh activity can induce the production of angiogenic factors, such as ascular endothelial growth factor-A (VEGF-A), and recruit immune cells like T regulatory cells (Tregs) and tumor-associated macrophages (TAMs), creating an immunosuppressive milieu. The Hh pathway also enhances the plasticity of the extracellular matrix, promoting cancer cell invasion. These elements interact in a complex manner between Hh signaling and the TME, forming a positive feedback loop that that not only fuels the growth and invasiveness of breast cancer but also confers resistance to therapies [18].

Fig. 2 Complex mechanisms of Hh pathway remodelling of TME in breast cancer. Hh signaling pathway plays a key role in the breast cancer microenvironment, affecting the function of tumor cells and immune cells. Treg cells often secrete inhibitory factors to hinder immune response. Hh signals regulate Treg/Th17 axis through metabolic remodeling, limit CD8 cell infiltration, and promote immune escape. TAMs polarize M2 under Hh signal, reduce CXCL9/10 production, inhibit CD8 T cell infiltration, and inhibit its function through PD-L1 expression. Hh signaling also reprograms CAFs to increase fibrocollagen and FGF5 expression, supporting tumor stem cell resistance. CCL2, CCL5 and IGF-1 secreted by CAFs activate the Hh signal in cancer cells, forming a vicious cycle that promotes tumor growth and drug resistance. CA-MSCs accelerate breast cancer bone metastasis by regulating immune response and promoting osteoblast differentiation. In addition, vascular endothelial growth factor (VEGF), pro-angiogenesis secretory molecules CYR61, IL-6, etc. all work synergically with Hh signaling pathway to strengthen the malignant behavior of breast tumor cells, promote the proliferation of cancer cells and enhance tumor drug resistance. Hypoxia and acidic tumor microenvironment are important factors that promote tumor invasion and metastasis and lead to poor prognosis of breast cancer patients

Immune cells and hh signaling

TAMs

It is well known that macrophages are a complex and heterogeneous group of cells that exhibit high plasticity when stimulated by various signals in TME. They can respond quickly and efficiently to participate in innate and adaptive immune responses [19]. Previous efforts employed to eliminate the TAMs in breast and lung cancer have yielded successful clinical outcomes [20]. The Hh signaling pathway, a key player in driving the polarization and proliferation of TAMs, has been the subject of recent studies. In both in vivo and in vitro experiments, tumor-derived Shh has been found to promote M2 polarization of TAMs in various malignant tumors, including hepatocellular carcinoma, lung cancer, breast tumors, and multiple myeloma [21–23]. The Shh can directly act on the tumor stroma to promote transcription factor Klf4-mediated M2 polarization. Subsequently, this process further suppresses the production of CXCL9 and CXCL10 in TAMs, reducing CD8 + T cell infiltration within the TME and fostering tumor growth [22]. Additionally, tumor cell-derived Shh ligand can drive the expression of PD-L1 in TAMs, causing dysfunction of CD8 + T cells within the tumor and promoting an immunosuppressive environment, which ultimately propels tumor progression [24]. Ann Hanna and colleagues have further confirmed that the application of inhibitors targeting this pathway even primed the M2 macrophages to respond more potently to inflammatory stimuli and set the macrophages on a path toward reverting to M1 macrophages [21]. Considering the close relationship between TAMs and Hh signaling in breast cancer, the inhibition of the Hh signaling pathway is expected to achieve the dual benefits of directly targeting tumor cells at TAM targets and reconfiguring the tumor immune microenvironment to an immune-activated state.

T lymphocytes

T lymphocytes are the most effective adaptive anti-tumor immune response mediators, and their abundance, functional activity, and spatial distribution are critical determinants of tumor prognosis and prediction [25]. Mature T lymphocytes are predominantly categorized into two types based on molecular markers: CD8 + and CD4 + cells. These two cell types work in concert to maintain the effective functioning of the immune system [26]. There is increasing evidence that Hh signaling plays a vital role in T cell production under physiological conditions by modulating tumor antigen-specific T cell receptors (TCRs). Increased Hh activity impacts TCR-induced calcium inflow and critical components of the TCR signaling pathway, thereby impacting TCR’s ability to transmit signals to T cells for activation and proliferation [27, 28]. Recent studies have indicated that Hh/Gli1 signaling has been shown to regulate the expression of immune checkpoint proteins such as PD1, CTLA-4, IL-10, etc. in T cells, as well as PD-L1/2, CD80/86, OX40L, CD137L, IDO, and CCL22 in cancer cells [29, 30]. Many studies have reported the correlation between the Hh signal and PD-L1 regulation, and PD-L1 on tumor-associated macrophages induced by the Hh signal can inhibit the function of tumor-infiltrating CD8 + T cells [24]. For example, Gli2 expression was found to be positively correlated with PD-L1 and negatively correlated with CD8 + T cell infiltration in gallbladder and gastric cancer tissues [31]. In the tumor immune microenvironment, Gli1 can directly bind the promoter of the transcription factor STAT3 and induce its expression, promote the transcription of PD-L1, and thus inhibit the effector function of CD8 + T cells [32]. In conclusion, the Hh signaling pathway can stimulate the expression of PD-L1 in various cell types, and increasing Hh activity may be a potential biomarker for predicting the therapeutic response of PD-1 inhibitors. Moreover, the combination of checkpoint inhibitors and Hh inhibitors will have more therapeutic advantages than treatment alone.

Tregs

Tregs are an immunosuppressive subpopulation of CD4 + T cells that maintain self-tolerance and protect against autoimmunity. Among them, the delicate balance between Tregs and Th17 has become essential in regulating immune homeostasis in breast cancer [33]. Hedgehog signaling regulates breast cancer microenvironment regulatory T/Th17 differentiation through metabolic remodeling and provides a means of immune evasion by breast cancer cells. Hh signaling promotes O-GlcNAc modifications of critical Tregs and Th17 transcription factors, Foxp3 and STAT3, respectively, that orchestrated the transition between Tregs and Th17. Moreover, recent experimental evidence has confirmed that when Hh signaling is inhibited, Tregs undergo a phenotypic shift towards a Th17-like state, accompanied by an enhanced inflammatory profile. Therefore, the blockade of the Hh pathway to reprogram Tregs and promote their conversion into pro-inflammatory Th17 cells may facilitate the creation of an immunological microenvironment conducive to tumor eradication in breast cancer [34]. The involvement of Hh signaling in the interplay between tumors and Tregs has also been demonstrated in other malignancies [35, 36]. In summary, the dynamic interplay between the Hh pathway and Tregs reveals the complexity of modulating the immune microenvironment in treating breast cancer.

Stromal cells and Hh signaling

CAFs

As an essential part of the tumor microenvironment, tumor-associated fibroblasts (CAFs) play an important role in the genesis and development of tumors. Activated CAFs reshape TME and influence malignant biological processes in cancer cells by altering transcriptional and secretory properties, and this regulation depends in part on the regulation of signaling cascades. With knowledge of the association between Hh and CAFs, the Hh signaling pathway activated in CAFs has been extensively studied [37]. It was found that CAFs infiltration was positively correlated with Hh activity, and the two had related biological functions [38]. As an essential signaling pathway in stem cells, the Hh signaling pathway in CAFs plays a vital role in regulating Breast Cancer Stem Cells (BCSCs). In a mouse model of triple-negative breast cancer (TNBC), Hh ligands produced by cancer cells are able to reprogram CAFs, providing support for the drug-resistant phenotype of Cancer Stem Cells (CSCs) through FGF5 expression and fibrous collagen production [39]. CAFs also activate Hh signaling in cancer cells by producing soluble mediators such as CCL2, CCL5, and IGF-1. They can all contribute to tumor progression in many ways, including enhancing proliferation, migration, and stem cell phenotypes [40, 41]. In addition to affecting CSCs, Hh signaling in CAFs also influences the development of other malignant biological behaviors. In gastric cancer, Galectin1 induces epithelial-mesenchymal transition (EMT), migration, and invasion of cancer cells by binding to the carbohydrate structure of integrin β1, activating Hh signaling, and up-regulating Gli1 expression [42]. Interestingly, Hh-mediated CAFs also engage in crosstalk with cancer cells that promote breast cancer progression and impact the efficacy of clinical antitumor therapies. Maria Peiris-Pages et al. have discovered that standard chemotherapy for cancer can induce the production of CAFs, leading to the establishment of a highly glycolytic phenotype, autophagy, and a pro-inflammatory microenvironment. This catabolic microenvironment activates stemness, antioxidant, and immune responses in breast cancer cells through paracrine Hh-Gli signaling [43]. Steele et al. have demonstrated that inhibition of the Hh signaling pathway reduces the number of myofibroblast CAFs while concurrently increasing the population of inflammatory CAFs [44]. Moreover, Aurelie S. Caazet et al. have demonstrated that treatment with a small molecule inhibitor (SMOi) of the Hh pathway can lead to a reduction in the expression of aldehyde dehydrogenase 1 (ALDH1) in cancer cells and an enhancement of the body’s sensitivity to docetaxel. This strategy has been shown to improve survival rates and reduce the metastatic burden in patients with invasive TNBC [39]. As researchers continue to explore CAFs in the tumor microenvironment, targeted CAFs therapies are expected to become an indispensable tool in the oncologists’ arsenal in the next decade.

MSCs

Mesenchymal stem cells (MSCs), endowed with stem cell characteristics and diverse regulatory activities on other cells, have become a focal point of interest due to their immunosuppressive and tumor-promoting mechanisms in cancer [45, 46]. Research has shown that MSCs facilitate the progression of breast cancer by activating signaling cascades involving intracellular transduction nodes [47, 48]. In the context of bone metastasis in breast cancer, the activation of the Hh signaling pathway in MSCs has been shown to promote osteoblast differentiation, collagen deposition by osteoblasts, and the suppression of natural killer (NK) cells via the inhibitory leukocyte associated immunoglobulin like receptor 1 (LAIR1) signaling pathway, thereby facilitating tumor colonization [49]. This suggests that targeted therapy against the Hh signaling pathway may present a novel treatment option for disorders of bone homeostasis. Future research is warranted to further elucidate the intricate relationship between the Hh signaling pathway and MSCs within the breast TME, and to understand how they collectively influence the onset and progression of breast cancer.

Secreted molecules and Hh signaling

VEGF

Angiogenesis represents the formation of new blood vessels and is a principal pathogenetic action in breast cancer. Vascular endothelial growth factor (VEGF) is a major angiogenesis regulator that modulates the maintenance and function of mature vascular networks [50, 51]. While the active hh signal in tumors has been extensively studied due to its conduction role in angiogenesis [52]. Shh has been found to induce the expression of angiopoietins and the VEGF family in mesenchymal cells to promote angiogenesis. And stimulate the production of secretory factors [53, 54]. At the same time, Concetta Di Mauro et al. found that Gli1-overexpressed cancer cells can not only induce the secretion of VEGF-A but also establish a secreted factor/receptor autocrine circuit to coordinate the vascularization of TNBC by upregulating VEGFR2 on the cancer cell surface [55]. Although many anti-angiogenic studies have focused on VEGF, it is Lillianne G. Harris and colleagues who identified a novel VEGF-independent transcriptional target of the Hh signaling pathway, the pro-angiogenic secretory molecule cysteine-rich angiogenic inducer 61 (CYR61), playing a significant role in breast cancer progression. CYR61 works in concert with the Hh ligand Shh to intensify the malignancy of breast cancer cells, stimulates robust tumor vascularization in vivo, and facilitates the spread of these cells through the bloodstream [56]. In addition, Hira Lal Goel et al. demonstrated that Gli1 regulates VEGF/neuropilin-2 (NRP2) and α6β1 integrated into mediated novel autocrine signaling pathways by enhancing the expression of VEGF receptor NRP2 to drive the initiation of TNBC [57]. Given the dynamic regulatory processes played by the Hh pathway in breast cancer angiogenesis, targeting the Hh signaling pathway offers new possibilities for replacing and mitigating resistance to conventional anti-angiogenic therapies, which has significant implications for clinical breast cancer management.

IL-6

Interleukin-6 (IL-6) is a pleiotropic cytokine involved in immune regulation that has an important impact on cancer progression through the activation of signaling cascades [58, 59]. In breast cancer, TAMs increase tumor initiation ability and chemotherapy resistance of tumor stem cells by secreting IL-6 [60], while also up-regulating circulating VEGF in breast cancer patients and promoting tumor angiogenesis and metastasis [61]. Xiao et al.‘s study has elucidated that the intricate relationship between the Hh pathway and IL-6 expression in breast cancer. They discovered that the inhibition of the Hh pathway not only leads to a significant up-regulation of IL-6 but also revealed a novel role for M2 macrophage-derived IL-6. This IL-6 acts as a protective mechanism for breast cancer cells against Hh inhibitors, suggesting its integral role in the maintenance and enhancement of the malignant potential of these cells [62]. In the future, antagonizing IL-6 and Hh pathway inhibitors may be a new therapeutic strategy for breast cancer.

Physical factors influencing Hh signaling

Hypoxic microenvironment

The hypoxic microenvironment is an essential driver of tumor progression, and hypoxia makes breast cancer more aggressive, metastatic, and drug-resistant than other tumors [63]. Hypoxia-inducing factor 1 (HIF-1), a principal regulator of the cellular response to hypoxic stress is intimately involved in nearly all critical steps of the metastatic process in breast cancer, including EMT, invasion, intravasation, extravasation, and the formation of a metastatic niche [64, 65]. Research has discovered that signaling pathways and molecules that remain inactive under normoxic conditions are often activated under hypoxic environments [66]. As a prominent feature of tumor growth, hypoxia affects several signaling circuits, including the Hh signaling, that converge during malignant progression. The Hh signaling pathway is often abnormally activated in breast cancer, promoting tumor progression and metastasis [67]. Tshering D.Lama-Sherpa et al. found that breast cancer with Hh activity can establish a hypoxic environment, which up-regulates the transcription levels of Hh pathway target genes Gli1, Gli2, and PTCH1 in breast tumor cells [68]. This hypoxic milieu, in turn, enhances HIF signaling in a Von Hippel-Lindau (VHL)-dependent manner, which is recognized for driving processes integral to breast cancer progression and metastasis, such as angiogenesis, metabolic reprogramming, and the acquisition of a more aggressive phenotype [68–70]. In addition, hypoxia enhances the ability of tumor cells to fight immune attacks, prompting tumors to adapt to evade immune surveillance [71]. It is well known that TME is closely related to hypoxia and Hh signaling activation. Therefore, the function of immune cells is also related to hypoxia and Hh signaling pathway. Studies have shown that the hypoxic areas in tumors contain more Myeloid-derived suppressor cells (MDSCs), TAMs, and Tregs [72, 73]. Hypoxic stress increases the cytotoxicity of CD8 + T cells while decreasing their proliferation and differentiation ability [73]. HIF-1α plays a crucial role in macrophage-mediated T-cell inhibition under hypoxic conditions [74]. The proliferation of activated lymphocytes was reduced under hypoxic conditions, but their migration did not change significantly. Under hypoxia in vitro, cell proliferation, migration, and cytotoxicity of activated TNK lymphocytes were significantly inhibited by Hh inhibitor treatment, and IFN-γ secretion was significantly increased [75]. The Hh signaling pathway plays a key role in activating TNK lymphocyte function. Hypoxia has been reported to induce overexpression of CCL28 to recruit Treg cells [76]. Hypoxia also enhanced immunosuppression by promoting treg activity [77]. It has been established that the function and differentiation of MDSCs in hypoxic TME are regulated by HIF-1α [78]. The polarization of aggressive bone marrow cells to MDSCs requires induction of the Hh pathway transcription factor Gli1, creating a microenvironment conducive to tumor transformation [79]. In conclusion, the association between hypoxia and Hh signaling may affect immune cell function. In the clinic, hypoxia often leads to radiation and chemotherapy resistance and immunosuppression, causing changes in the TME, which is a significant obstacle to cancer treatment effectiveness [78]. At the cellular level, inhibiting Hh signaling can effectively improve tumor hypoxic landscape and reduce tumor metastasis potential. At the molecular level, blocking the Hh signaling pathway can significantly weaken the ability of tumor cells to adapt to an anoxic environment. Based on this, the study of Hh signaling pathway inhibitors provides a new strategy and perspective for clinical treatment in preventing hypoxic-mediated breast cancer progression and metastasis.

Tumor acidification

The tumor microenvironment plays a vital role in tumor formation and development, and acidity is one of the significant characteristics of the tumor microenvironment [80]. Aerobic glycolysis-mainly attributable to chronic activation of HIF-1-and tumor hypoxia, are chiefly responsible for this phenomenon [81]. This particular microenvironment promotes gene reprogramming of tumor cells, promotes tumor invasion and metastasis, and is an essential factor leading to poor prognosis in breast cancer patients [82]. Carbonic anhydrases (CAs) constitute a family of enzymes integral to the regulation of pH homeostasis in living organisms. They modulate the extracellular pH by facilitating the reversible interconversion between carbon dioxide and bicarbonate [83]. In breast cancer cells, the expression and activity of CAs are dysregulated, contributing to the exacerbation of the tumor acidification [84]. Giuditta Guerrini and colleagues have elucidated the role of the Hh signaling pathway in the regulation of Carbonic Anhydrase isoform XII (CAXII) expression.By targeting the SMO component of the Hh pathway, it is possible to diminish CAXII expression at both the mRNA and protein levels, subsequently impeding the migration and invasion of breast tumor cells [85]. This discovery implicates the Hh pathway as a promising therapeutic target for the treatment of breast cancer. Tumor cells engineer their microenvironment by creating an acidic milieu that is non-toxic to malignant cells, thereby facilitating local invasion. Consequently, from a therapeutic standpoint, identifying strategies to reduce the pH surrounding the tumor could potentially offer a valuable adjunct or alternative to the traditional approach of exclusively targeting tumor cell eradication in the future.

Crosstalk between Hh signaling and other pathways in breast cancer

The intricate cellular cascades play a pivotal role in the evolution of cancer, with an increasing body of evidence highlighting the Hh pathway as a central player within the breast cancer microenvironment. Herein, we elucidate the collaborative mechanisms of Hh signaling with Wnt/TGF-β/Notch/RAS/MAPK/NF-κβ/PI3K pathways to govern a spectrum of functions, including cell proliferation, apoptosis, migration, and epithelial-mesenchymal transition (Fig. 3).

Fig. 3 Communication between the Hh signalling pathway and other pathways in breast cancer TME. The regulatory role of Hh signaling pathway in breast cancer is complex, involving a variety of signaling pathways, including Wnt/TGF-β/Notch/RAS/MAPK/NF-κβ/PI3K pathways. They have direct effects on target genes or activation of transcription factors through various mechanisms to affect cell behavior. For example, in the crosstalk with the North pathway, Hh promotes tumor cell proliferation and inhibits apoptosis by regulating its key target gene jagged2. In addition, Shh does not require γ-secretase to cut Notch receptor, and can directly act on Hes1 to promote tumor cell development. In endocrine-resistant breast cancer, activation of PI3K/AKT pathway receptors such as EGFR and IGF1-R stabilizes SMO and Gli1 proteins by affecting GSK3β-mediated phosphorylation and proteasome degradation. In the NF-κB pathway, various stimuli (such as TNF-α) activate the IκB kinase (IKK) complex and phosphorylate the IκB inhibitory protein, leading to ubiquitination and subsequent degradation of the IκB protein, thereby releasing proteins of the NF-κB family (such as P65, P50, etc.), mediating the up-regulation of Gli1 and SHh expression. In TGF-β pathway, the formation of complexes between phosphorylated Smad2/3 and Smad4 can effectively induce Gli1, Gli2 and their target gene PTH-rP (osteoclast formation regulator), and promote osseolytic metastasis of breast cancer. The RAS pathway phosphorylates and activates MEK (MAPKK) and ERK (MAPK) in sequence through integrin conduction and downstream effector Raf activation in the absence of Hh ligand, and finally the activated ERK enters the nucleus to activate Hh signaling pathway ligand GLI. In the Wnt pathway, the key molecule β-catenin enhances the transcriptional activity of GLI and participates in the Hh signaling pathway. In the absence of Hh signaling, the transcription factor Gli3 (Gli3R) interacts with the carboxy-terminal domain of β-catenin, blocking classical Wnt signaling. This mechanism may provide reference for the development of cancer treatment drugs

Notch signaling pathway

The Notch signaling pathway is frequently deregulated in several human malignancies, which has been described as a primary culprit (one of the three members of the so-called axis of evil) in breast cancer; the other two are HER2 and cancer stem cells [86]. In a manner analogous to Hh signaling, the activity of the Notch pathway has increasingly become a focus of research within the subpopulation of BCSCs [87, 88]. Genetic evidence in mice, as well as molecular biological studies in human cells, clearly indicate that the balance between Notch and Hh signaling networks is important for the maintenance of homeostasis among stem and progenitor cells [89]. Furthermore, the dysregulated Hh signaling, in conjunction with the Notch and Wnt pathways, is involved in the maintenance of embryonic stem cell self-renewal and is regulated during the self-renewal and differentiation of adult stem cells [90]. During carcinogenesis, the Hh signals induce Notch pathway ligand JAG2 to promote tumor cell proliferation and inhibit cell apoptosis [91]. Similarly, Hes1, a target protein of the Notch signaling pathway, is upregulated by the Shh through a mechanism that bypasses the canonical Notch signaling pathway. This finding underscores the complexity of the crosstalk between the Hh and Notch signaling pathways [92]. Given the complexity of the specific interplays between the Hh and Notch pathways, the mechanisms underlying their crosstalk are currently under intensive investigation. A study assessing the combined inhibition of Hh and Notch in advanced breast cancer (NCT01071564) is underway, which may pave the way for establishing the safety of a combined therapeutic approach [93].

PI3K/AKT/mTOR signaling pathway

Endocrine therapy resistance is a predominant clinical challenge in the management of estrogen receptor (ER)-positive breast cancer, with one of the significant hurdles in treating this illness being great crosstalk in tumor pathways. Among these pathways, the PI3K/AKT/mTOR pathway has been recognized as a substantial contributor to endocrine resistance [94]. Contemporary research has revealed crosstalk between the PI3K/AKT and the Hh pathways that can contribute to the development of tamoxifen resistance. Specifically, in tamoxifen-resistant cells, the activation of the PI3K/AKT pathway has been shown to attenuate the proteasomal degradation of key components of the Hh pathway, Gli1 and SMO, leading to the atypical activation of the Hh signaling cascade [95]. Gli1, a positive transcriptional effector of the Hh signaling pathway, has been demonstrated to be significantly upregulated under conditions of serum starvation, where activation of the PI3K/AKT pathway enhances the expression of the Gli1 gene. This upregulation of Gli1 is associated with a prosurvival role in breast cancer [96]. Additionally, a multitude of studies have indicated that PI3K/Akt/mTOR inhibitors and Hh inhibitors have synergistic effects, suggesting that the concurrent use of these two classes of signaling modulators can delay the emergence of drug resistance and curb cancer metastasis in breast cancer [97–99]. For example, the combination therapy using sonidegib (SMO inhibitor) and buparlisib (PI3K kinase inhibitor) treating metastatic breast cancer has been in phase Ib study (NCT01576666). These discoveries have furnished evidence for the interplay between the Hh signaling and PI3K/Akt/mTOR signal transduction in breast cancer. Therefore, the concurrent targeting of these two pathways is imperative for addressing the issue of endocrine resistance in patients with advanced hormone-refractory breast cancer.

NF-κB signaling pathway

Nuclear factor-kappa B (NF-κB) is a crucial transcription factor, the activation of which is a significant common mechanism in the metastasis and therapeutic progression of breast cancer [100, 101]. Numerous reports have described a bidirectional regulation between Notch and NF-κB through various context-dependent mechanisms. Clinical studies have identified elevated levels of Shh in breast cancer tissues with positive nuclear staining for NF-κB and hypomethylation of the promoter region [102]. Further in vitro experiments have elucidated the relationship between Shh, NF-κB, and promoter methylation. Specifically, hypomethylation within the Shh promoter facilitates the binding of NF-κB to its cognate sites, subsequently cooperating to induce the transcription of Shh [103]. Overexpression of the Shh gene continually enhances the self-renewal and migratory capabilities of breast cancer cells, providing new insights into the role of Shh in promoting malignant behavior in breast cancer. In addition, Sierra A Colavito et al. offered direct evidence of the binding of NF-κB subunit p65 to Gli1 promoters in EMT and claudin-low cell lines, revealing crosstalk between NF-κB and Gli1 signaling. They suggest that targeting these pathways may be effective against the claudin-low breast cancer subtype [104]. Sinomenine suppressed the activation of Shh by blocking the NF-κB pathway and alleviated the progression of breast cancer lung metastasis in mice in vivo [105]. Hh pathway-specific small molecule inhibitors also suppress the invasive capabilities of breast cancer cell lines by inhibiting the expression levels of NF-κB, MMP2, and MMP9 proteins [106]. These findings indirectly substantiate the entangled crosstalk between the two pathways. Elucidating the molecular mechanisms underlying the cross-regulation between Hh and NF-κB may pave the way for developing synergistic therapeutic strategies to enhance the efficacy of breast cancer treatment in the future.

TGF-β signaling pathway

TGF-β is a pleiotropic cytokine and multifunctional growth factor that plays a complex role in the pathogenesis of breast cancer [107, 108]. TGF-β acts as a tumor suppressor in the early stages of the disease and as a tumor promoter in its later stages [109]. Its intercommunication and crosstalk with diverse signaling pathways augment the potential for exploring it as an integrative biomarker. The TGF-β signaling pathway crosstalk with Hh signaling, resulting in the acquisition of mesenchymal phenotypes, enhanced growth, and TNBC invasion [110]. The TGF-β/SMAD cascade is often considered a potent inducer of Gli2 [111]. In the pathological state of TGF-β induced cancer fibrosis, reactivation of the Hh signal will lead to more fibrosis [112]. Jitesh Pratap and colleagues have demonstrated that Gli2 and its target gene PTH-rP, a regulator of osteoclast formation, are upregulated in response to TGF-β signaling, and this process plays a pivotal role in the osteolytic metastasis of TNBC [113]. Consequently, this exciting discovery opens up new possibilities for treatment, as targeting the TGF-β and Hh signaling pathways in breast cancer bone metastasis may inhibit osteoclast activation and bone erosion, effectively delaying cancer progression.

RAS/MAPK signaling pathway

A growing body of preclinical evidence supports the targeting of the Ras/MAPK signaling pathway in the TNBC subtype, despite the infrequency of atypical mutations in this pathway as indicated by large-scale genomic surveys, such as The Cancer Genome Atlas [114, 115]. However, studies have identified that the Ras signaling pathway is capable of activating GLI target genes downstream of SMO in a manner independent of Hedgehog ligand engagement [116]. Arthur M. Mercurio and colleagues have revealed a novel autocrine signaling pathway in TNBC mediated by VEGF/NRP2 and α6β1 signaling. This signaling cascade activates a FAK-dependent RAS/MEK signaling enhancement, leading to increased expression of Gli1. Significantly, Gli1, in turn, stimulates the expression of NRP2, establishing a positive feedback loop that sustains this autocrine pathway [57]. In vitro, human recombinant Shh has been shown to directly upregulate the expression of MAPK and activate the p38/MAPK-activated protein kinase (MK2), thereby exerting a novel role in promoting glycolysis and proliferation in breast cancer cells [117]. Additionally, the natural Hh pathway inhibitor cyclopamine has been shown to induce a robust G1 cell cycle arrest and significantly impact the expression of the cell cycle protein cyclin D1 through modulation of the MAPK/ERK signaling pathway [106]. Cancerous and non-mutational abnormal RAS signaling has been found to enhance the function of Gli1 in pancreatic, gastric, and breast cancers through multiple mechanisms. These include enhancing its transcriptional activity, promoting its nuclear translocation, inhibiting Sufu-mediated cytoplasmic sequestration, and suppressing proteasome-mediated degradation [57, 118, 119]. These findings suggest that RAS and Hh signaling pathways may have a synergistic role in tumor formation or maintenance. KRAS, a particular member of the RAS gene family, is frequently mutated in pancreatic cancer and has been found to activate the function of GLI downstream of SMO significantly. However, this effect is independent of Hedgehog ligands, as the Hh inhibitor cyclopamine does not reverse the overactivation of GLI induced by oncogenic KRAS [120, 121]. In addition, Morton et al. reported a positive interaction between Hh and KRAS, suggesting that cotransduction of Shh and KRAS significantly enhanced cell proliferation and tumor growth in non-cancerous pancreatic duct epithelial cells compared to single gene transduction [122]. It is noteworthy that the interplay between RAS and GLI may be more complex than what current research has revealed. The existence of this intriguing mechanistic effect in breast cancer warrants further exploration.

Wnt signaling pathway

The Wnt signaling pathway is a developmental signaling cascade that plays a crucial role in regulating normal mammary gland development. Aberrant activation of this pathway can lead to hyperplasia of the breast and tumorigenesis [123, 124]. In recent years, the crosstalk between the Hh and Wnt signaling pathways has been established as having significant clinical implications in the progression of breast cancer. β-catenin, a vital molecule of the Wnt signaling pathway, participates in the Hh signaling pathway by enhancing GLI transcriptional activity [125]. It is noteworthy that the Hh-regulated transcription factor Gli3, produced in the absence of Gli3R, can interact with the C-terminal domain of β-catenin to inhibit the canonical Wnt signaling pathway [126]. Researchers such as Arnold, K. M. et al. found that co-activation of Hh and Wnt signaling pathways is associated with poorer prognosis in patients with TNBC and that this crosstalk may lead to an increased risk of early cancer recurrence and shorter overall survival [127]. Therefore, the joint activation status of Hh and Wnt signaling pathways may serve as an effective indicator for predicting the risk of early recurrence in TNBC patients. Monitoring their activation status can help identify patients who are resistant to treatment and at risk for early relapse, and this combined analysis may hold more valuable prognostic information than considering either pathway alone.

Inhibitors of the hedgehog signalling pathway targeting TME in breast cancer

Due to the essential and multiple roles of Hedgehog signaling in the TME, novel molecular therapies targeting this pathway have shown unlimited prospects. A variety of Hedgehog pathway inhibitors have been developed and can be divided into different classes based on their targets in the pathway, including SMO inhibitors (e.g. Cyclopamine, GDC-0449), HH inhibitors (e.g. 5E1, RU-SKI 43) and GLI inhibitors (e.g. GANT61, Arsenic trioxide). Figure 4 highlights current Hh signaling pathway inhibitors targeting TME in breast cancer.

Fig. 4 Hh signalling pathway inhibitors targeting TME in breast cancer. Utilizing a multitude of promising approaches to inhibit the Hh signaling pathway may offer significant contributions to therapeutic strategies for breast cancer treatment. Current inhibitors targeting Hh signaling include small molecule inhibitors and natural compounds. These small molecule inhibitors are broadly categorized into: SMO inhibitors (e.g., Cyclopamine, Vismodegib, Sonidegib), HHh inhibitors (e.g., 5E1, RU-SKI 43), and GLI inhibitors (e.g., GANT61, Arsenic trioxide [ATO], HPI-1, JK184). In addition, several naturally occurring compounds have been identified as inhibitors of the Hh signaling pathway, such as Huaier aqueous extract, Genistein from soy and other plants, Cananginones from Annona, Pterostilbene from blueberries and grapes, Solasodin from Solanum incanum L, Sinomenine from Sinomenium acutum, Curcumin from Curcuma longa L, Physalin A from Physalis alkekengi, Wogonoside from Scutellaria baicalensis Georgi, Nitidine Chloride from Zanthoxylum nitidum (Roxb.) DC, Norcantharidin from Mylabris phalerata Pallas, and Cordycepin from Cordyceps militaris

The first class is SMO inhibitors. Small molecule SMO antagonists target Hh signaling by binding to the pockets within the extracellular domain (ECD) and the transmembrane domain (TMD) of SMO [128]. Cyclopamine, recognized as the inaugural Hh signaling pathway inhibitor, has revealed its multifaceted potential in targeting the TME. It potently suppresses the SMO-GLI signaling cascade, consequently downregulating the expression of GLI target genes, such as cyclin D1 and BCL2. This downregulation is crucial for inhibiting EMT in breast cancer cells, a process fundamental to the metastatic cascade. Additionally, cyclopamine attenuates the secretion of matrix metalloproteinases (MMP-9 and MMP-2), enzymes that are significantly implicated in tumor invasiveness and metastasis. Through these mechanisms, cyclopamine exerts a synergistic effect on the inhibition of anchorage-independent growth in oncogenic breast cancer cells, markedly reducing tumor proliferation and promoting apoptosis [129, 130]. In the modulation of the tumor’s acidic microenvironment, cyclopamine also plays a constructive role. It diminishes the expression of carbonic anhydrase II (CAXII), an enzyme pivotal to establishing the TME’s acidic milieu. By mitigating the acidic status of the TME, cyclopamine impairs the migratory capacity of breast cancer cells, thereby curtailing their propensity for proliferation and metastasis [85]. Moreover, cyclopamine has demonstrated significant efficacy in inhibiting the Hh signaling pathway within CSCs. It prevents the overexpression of GLI proteins and the upregulation of the BMI-1 gene, factors that are intimately associated with the self-renewal and tumorigenic potential of CSCs. Through these actions, cyclopamine suppresses the number and proliferation rate of CSCs and diminishes the expression of the stemness marker ALDH1, which is of paramount importance for the management of tumor recurrence and metastasis [131]. GDC-0449 or Vismodegib, was the first FDA-approved small molecule as an SMO inhibitor for use in the treatment of Basal Cell Carcinoma (BCC) and is currently included in a clinical trial of the combination in TNBC [67, 132]. Studies have confirmed that treatment with Vimodegib enhances the efficacy of breast cancer chemotherapy by normalizing the TME through a reduction in proliferative CAFs and, in some cases, the levels of collagen and hyaluronan [133]. Meanwhile, the administration of Vismodegib induces changes in the portfolio of breast cancer tumor-infiltrating immune cells, reprogramming the dysfunctional immune microenvironment [21].

Sonidegib, another potent and selective oral SMO inhibitor, significantly reduced alkaline phosphatase (ALP) activity in a mouse model of breast cancer metastasis and restored NK cell infiltration at the site of bone metastasis, thereby inhibiting ER-positive breast cancer colonization [49]. In addition, the antifungal drug itraconazole has been reassessed as an inhibitor of the Hh signaling pathway as it prevents the ciliary accumulation of SMO and acts on the Hh pathway [134]. It was found that itraconazole effectively inhibited angiogenesis and reduced tumor blood perfusion by selectively inhibiting VEGF signaling in MCF-7 cells in the breast cancer microenvironment [135, 136].

While the majority of Hh pathway inhibitors target the transmembrane protein SMO, some small molecules that target the signaling cascades upstream and downstream of SMO to remodel the TEM have also attracted particular interest from researchers.

The most prominent drug candidate that works upstream of SMO is the 5E1 monoclonal antibody. Related studies have highlighted the importance of the stroma in Hh-mediated tumor growth and that the monoclonal antibody 5E1 can inhibit breast cancer growth by affecting Hh signaling in the stroma [137]. Palmitoylation is a post-translational modification essential for Hedgehog signaling. Hedgehog acyltransferase (Hhat), a member of the membrane-bound O-acyltransferase (MBOAT) family, achieves palmitoylation modification of Shh by catalyzing the covalent attachment of palmitate to the N-terminus of Hedgehog proteins [138]. Notably, RU-SKI 43, a small molecule inhibitor, can target the activity of Hhat to directly inhibit shh palmitoylation, thereby reshaping the breast cancer microenvironment andsuppressing tumor proliferation [139, 140].

Compared to targeting SMO upstream targets, downstream GLI inhibitors have demonstrated broader applicability in intervening in TME treatment strategies. In particular, GANT61, the first GLI inhibitor to be discovered, has been investigated in various tumor types in recent years [141]. It was found that GANT61 interferes with TME reprogramming by inhibiting FGF5 activation and collagen fiber secretion in CAFs, thereby reducing the number of CSCs in TNBC and achieving tumor stem cell plasticity [142]. It was confirmed that EMT-transcription factors are closely associated with activated Hedgehog/GLI signaling in human breast tumors [143]. Of interest, EMT cells can promote breast cancer metastasis through non-cell-autonomous activation of the GLI transcriptional program in neighboring epithelial tumor cells. However, applying GANT61 blocked this effect and inhibited growth in the PDX model [143]. Furthermore, treatment with GANT61 in immunocompetent mouse models of breast cancer induces significant alterations in the TME, characterized by an increase in cytotoxic immune cells and a decrease in immunosuppressive innate and adaptive cells [21]. In pharmacological experiments, GANT61 not only targets and inhibits the proliferation and growth of inflammatory breast cancer cells but also effectively reduces the formation of tumor emboli, lowering the risk of tumor metastasis and the likelihood of embolism [144]. It is evident that GANT61 is one of the most compelling antagonists. Unfortunately, current evidence of efficacy is limited to the preclinical drug development stage [145].

Arsenic trioxide (ATO), a drug that has been approved by the FDA for the treatment of acute promyelocytic leukaemia (APL), has been shown to participate in preclinical trials as a GLI destabiliser [146]. This is attributed to the fact that by blocking ciliary transport and promoting destabilisation of the Gli2 protein, ATO effectively inhibits downstream components of the Hedgehog signalling pathway [147].

It is well known that metabolic reprogramming is essential for the establishment of TME in breast cancer [148]. ATO was found to reduce the protective effect of CAFs on breast cancer cells by uncoupling metabolism between epithelial cancer cells and fibroblasts in the TME, which is an essential strategy for preventing resistance to anti-estrogenic drugs. At the same time, ATO increased ROS production and was able to inhibit the mitochondrial electron transport chain, thereby increasing glycolytic processes and optimizing the TME [149]. Furthermore, ATO also promotes the release of high mobility group protein B1 (HMGB1), transforming “cold” tumors, which are unattractive to immune cells, into “hot” tumors, which are more attractive to immune cells, thus promoting immune cell infiltration and identification of new targets [150].

Another class of potent antagonists of the Hh transcription factor Gli1, HPI-1, disrupt GLI transport to primary cilia and ciliogenesis in a different manner, functioning independently of upstream components of the pathway [151, 152]. HPI-1 has been reported to significantly reduce the percentage of cancer stem cells in breast cancer cells and is a candidate for targeting breast cancer stem cells [153]. In recent years, JK184 has shown great promise in cancer therapy by virtue of its specific inhibition of GLI in the Hedgehog pathway. On the one hand, in the 3D tumor spheroid assay, JK184 was able to significantly reduce the size and number of tumor spheroids formed by SUM149 cells, suggesting that JK184 may have an inhibitory effect on tumor cell aggregation and tumor embolus formation [144]. On the other hand, JK184 was more effective in inhibiting the proliferation of EMT cells, which was associated with the fact that EMT cells exhibited high Gli1 expression [104].

Over the past few years, natural products have provided an unrivaled supply of anti-cancer drugs. The use of natural compounds and their derivatives to modify the TME and Hh signaling pathways offers an attractive approach to treating tumors. Here, we emphasize the potential of phytochemicals to target the Hh signaling pathway and remodel TME in breast cancer therapy (Table 1).

Table 1 Summary of phytochemicals targeting hedgehog signalling to intervene in TME in breast cancer

Drugs	Natural sources	Proposed Mechanism	Reference	
Genistein	Soy and other plants	Decrease Breast cancer stem cells (BCSCs) by downregulating the Hedgehog-Gli1 Signaling Pathway	[154]	
Pterostilbene	Blueberries, grapes, etc.	Reduce BCSCs stemness by inhibiting the hedgehog/Akt/GSK3β signaling	[155]	
Curcumin	Curcuma longa L	Inhibit EMT and characteristics of BCSCs by targeting the Hedgehog/Gli1 pathway	[156]	
Nitidine Chloride	Zanthoxylum nitidum (Roxb.) DC	Suppresse breast cancer EMT and CSCs-like properties by inhibiting Hedgehog signaling pathway	[157]	
Cananginones	Annona	Abrogate cancer stem cell renewal as well as EMT and increase the ROS level by inhibiting Gli1 in a non-canonical pathway	[158]	
cordycepin	Cordyceps militaris	Block EMT by inhibiting expression of Hh pathway components and GLI transcriptional activity	[159, 160]	
Sinomenine	Sinomenium acutum	Suppress the activation of NF-κB and Shh signaling pathways	[105]	
Wogonoside	Scutellaria baicalensis Georgi	Attenuate growth and angiogenesis by inhibiting Gli1 nuclear translocation and transcriptional activities associated with Hedgehog signaling	[161]	
Solasodine	Solanum incanum L	Target CSCs suppressing Hh/Gli1 signaling	[162]	
Norcantharidin	Mylabris phalerata Pallas	Overcome multidrug resistance by inhibiting Shh signaling and expression of its downstream mdr-1/P-gp expression	[163]	
Physalin A	Physalis alkekengi	Reduce CSC marker genes by reducing Gli1 gene expression	[164]	
Huaier aqueous extract	Huaier	Eliminate the breast cancer stem cells through inactivation of the Hh pathway	[165]	

Conclusion and prospect

Breast cancer is the leading cause of cancer morbidity and mortality in women worldwide, characterized by poor prognosis, early recurrence, high invasiveness, and a high degree of metastasis [166, 167]. These adverse outcomes can be partly attributed to complex TME [168, 169]. Within this tumor nest, the interrelations among various components constitute a three-dimensional network. The Hh signaling pathway, a pivotal modulator of developmental processes and stem cell fate, resides at the epicenter of this network. Collective evidence to date indicates that aberrant activation of the Hh signaling pathway exerts regulatory control over the cellular constituents within the breast cancer TME and is engaged in interactions with physical factors. Beyond the interplays above, the Hh signaling cascade also induces crosstalk among numerous signaling pathways, culminating in the formation of a complex regulatory network, which further extends the proliferative potential of this pathway in human cancers. This complex interplay results in the hallmark invasive characteristics of breast cancer, such as the development and maintenance of cancer stem cells, EMT, therapeutic resistance, and immune evasion. Therefore, gaining a more profound understanding of the crosstalk between the Hh signaling and the TME may pave the way for developing novel therapeutic strategies to halt breast cancer progression.

Over the past decade, the targeting of specific signaling pathways has revolutionized the management of certain cancers. The critical oncogenic role of the Hh signaling pathway has spurred efforts to identify small molecule inhibitors of this pathway. Inhibitors targeting the Hh signaling pathway have been demonstrated to exhibit significant efficacy in the treatment of advanced and metastatic basal cell carcinoma [170, 171]. That said, they still carry the risk of drug resistance, which is mainly attributed to point mutations in the drug binding pocket of the SMO protein or downstream molecules, as well as the activation of compensatory pathways such as PI3K/AKT [172–175]. Furthermore, unfavorable solubility and suboptimal pharmacokinetic (PK) properties also constrain the therapeutic success of Hh antagonists [176]. Fortunately, researchers have developed several drug delivery systems to overcome many of these challenges [177, 178]. For example, the superparamagnetic iron oxide nanoparticle formulation of curcumin enhances gemcitabine therapeutic response via suppression of the Shh pathway and an oncogenic CXCR4/CXCL12 signaling axis that inhibits bidirectional tumor-stromal cell interaction [179]. Concurrently, targeted therapies that act on the Hh pathway must be approached cautiously due to the potential for inducing numerous side effects and drawbacks. GDC-0449 and Vismodegib have demonstrated the ability to elicit objective responses in patients with locally advanced and metastatic basal cell carcinoma. However, adverse events, including taste disturbances, muscle spasms, and alopecia, have led to treatment discontinuation in most patients [171, 180]. In a phase I clinical study, the combination of sonidegib plus docetaxel (fixed dose at 75 mg/m2) for the treatment of TNBC patients also resulted in a series of Grade 3 adverse events [181]. Therefore, there is an urgent need to elucidate the specific conditions and processes underlying the activation of the Hh pathway and to identify additional and superior strategies for inhibiting oncogenic Hh signaling.

Acknowledgements

Thanks to Biorender (www.biorender.com) for the drawing materials.

Author contributions

Ruijuan Liu, Yang Yu and Qingyang Wang designed the framework of this article. Ruijuan Liu and Qianxiang Zhao are coresponsible for the collection, and writing of the original manuscript. Yan Yao and Mengxuan Sun revised the details of the manuscript and created visualizations. Jing Zhuang, Changgang Sun and Yuanfu Qi responsible for the review of the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This study was supported by the Natural Science Foundation of Shandong Province (ZR2021LZY015), Traditional Chinese Medicine Science and Technology Project of Shandong Province (Z-2022021) and Qingdao Municipal Science and Technology Benefit the People Demonstration Project (23-2-8-smjk-1-nsh).

Data availability

No datasets were generated or analysed during the current study.

Declarations

Competing interests

The authors declare no competing interests.

Abbreviations

TME Tumor microenvironment

Hh Hedgehog

TNBC Triple-negative breast cancer

SMO Smoothened

Shh Sonic Hedgehog

IHh Indian Hedgehog

DHh Desert Hedgehog

TAMs Tumor-associated macrophages

TCRs T cell receptors

Tregs T regulatory cells

CAFs Tumor-associated fibroblasts

BCSCs Breast Cancer Stem Cells

MSCs Mesenchymal stem cells

NK Natural killer

VEGF Vascular endothelial growth factor

CYR61 Cysteine-rich angiogenic inducer 61

NRP2 Neuropilin-2

IL-6 Interleukin-6

HIF-1 Hypoxia-inducing factor 1

EMT Epithelial-mesenchymal transition

MDSCs Myeloid-derived suppressor cells

CAs Carbonic anhydrases

CAXII Carbonic Anhydrase isoform XII

ER Estrogen receptor

NF-κB Nuclear factor-kappa B

TGF-β Transforming growth factor β

MK2 P38/MAPK-activated protein kinase

ECD Extracellular domain

TMD Transmembrane domain

BCC Basal Cell Carcinoma

ALP Alkaline phosphatase

Hhat Hedgehog acyltransferase

MBOAT Membrane-bound O-acyltransferase

ATO Arsenic trioxide

APL Acute promyelocytic leukaemia

HMGB1 High mobility group protein B1

LAIR1 Leukocyte associated immunoglobulin like receptor 1

VHL Von Hippel-Lindau

ALDH1 Aldehyde dehydrogenase 1

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ruijuan Liu, Yang Yu and Qingyang Wang contributed equally to this work.
==== Refs
References

1. de Visser KE Joyce JA The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth Cancer Cell 2023 41 3 374 403 10.1016/j.ccell.2023.02.016 36917948
de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374–403.36917948 10.1016/j.ccell.2023.02.016
2. Labani-Motlagh A Ashja-Mahdavi M Loskog A The Tumor Microenvironment: a Milieu Hindering and Obstructing Antitumor Immune responses Front Immunol 2020 11 940 10.3389/fimmu.2020.00940 32499786
Labani-Motlagh A, Ashja-Mahdavi M, Loskog A. The Tumor Microenvironment: a Milieu Hindering and Obstructing Antitumor Immune responses. Front Immunol. 2020;11:940.32499786 10.3389/fimmu.2020.00940
3. Bejarano L Jordao MJC Joyce JA Therapeutic Target Tumor Microenvironment Cancer Discov 2021 11 4 933 59 33811125
Bejarano L, Jordao MJC, Joyce JA. Therapeutic Target Tumor Microenvironment Cancer Discov. 2021;11(4):933–59.33811125
4. Fidler IJ Kripke ML The challenge of targeting metastasis Cancer Metastasis Rev 2015 34 4 635 41 10.1007/s10555-015-9586-9 26328524
Fidler IJ, Kripke ML. The challenge of targeting metastasis. Cancer Metastasis Rev. 2015;34(4):635–41.26328524 10.1007/s10555-015-9586-9
5. Jing J Hedgehog signaling in tissue homeostasis, cancers, and targeted therapies Signal Transduct Target Ther 2023 8 1 315 10.1038/s41392-023-01559-5 37596267
Jing J, et al. Hedgehog signaling in tissue homeostasis, cancers, and targeted therapies. Signal Transduct Target Ther. 2023;8(1):315.37596267 10.1038/s41392-023-01559-5
6. Hassounah NB Inhibition of ciliogenesis promotes hedgehog signaling, Tumorigenesis, and metastasis in breast Cancer Mol Cancer Res 2017 15 10 1421 30 10.1158/1541-7786.MCR-17-0034 28611083
Hassounah NB, et al. Inhibition of ciliogenesis promotes hedgehog signaling, Tumorigenesis, and metastasis in breast Cancer. Mol Cancer Res. 2017;15(10):1421–30.28611083 10.1158/1541-7786.MCR-17-0034
7. Habib JG O’Shaughnessy JA The hedgehog pathway in triple-negative breast cancer Cancer Med 2016 5 10 2989 3006 10.1002/cam4.833 27539549
Habib JG, O’Shaughnessy JA. The hedgehog pathway in triple-negative breast cancer. Cancer Med. 2016;5(10):2989–3006.27539549 10.1002/cam4.833
8. Zhang J Hedgehog signaling in gastrointestinal carcinogenesis and the gastrointestinal tumor microenvironment Acta Pharm Sin B 2021 11 3 609 20 10.1016/j.apsb.2020.10.022 33777671
Zhang J, et al. Hedgehog signaling in gastrointestinal carcinogenesis and the gastrointestinal tumor microenvironment. Acta Pharm Sin B. 2021;11(3):609–20.33777671 10.1016/j.apsb.2020.10.022
9. Jiang J Hedgehog signaling mechanism and role in cancer Semin Cancer Biol 2022 85 107 22 10.1016/j.semcancer.2021.04.003 33836254
Jiang J. Hedgehog signaling mechanism and role in cancer. Semin Cancer Biol. 2022;85:107–22.33836254 10.1016/j.semcancer.2021.04.003
10. Briscoe J Therond PP The mechanisms of hedgehog signalling and its roles in development and disease Nat Rev Mol Cell Biol 2013 14 7 416 29 10.1038/nrm3598 23719536
Briscoe J, Therond PP. The mechanisms of hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol. 2013;14(7):416–29.23719536 10.1038/nrm3598
11. Liu A Wang B Niswander LA Mouse intraflagellar transport proteins regulate both the activator and repressor functions of gli transcription factors Development 2005 132 13 3103 11 10.1242/dev.01894 15930098
Liu A, Wang B, Niswander LA. Mouse intraflagellar transport proteins regulate both the activator and repressor functions of gli transcription factors. Development. 2005;132(13):3103–11.15930098 10.1242/dev.01894
12. Hebrok M Regulation of pancreas development by hedgehog signaling Development 2000 127 22 4905 13 10.1242/dev.127.22.4905 11044404
Hebrok M, et al. Regulation of pancreas development by hedgehog signaling. Development. 2000;127(22):4905–13.11044404 10.1242/dev.127.22.4905
13. Petrova R Joyner AL Roles for hedgehog signaling in adult organ homeostasis and repair Development 2014 141 18 3445 57 10.1242/dev.083691 25183867
Petrova R, Joyner AL. Roles for hedgehog signaling in adult organ homeostasis and repair. Development. 2014;141(18):3445–57.25183867 10.1242/dev.083691
14. Blotta S Canonical and noncanonical hedgehog pathway in the pathogenesis of multiple myeloma Blood 2012 120 25 5002 13 10.1182/blood-2011-07-368142 22821765
Blotta S, et al. Canonical and noncanonical hedgehog pathway in the pathogenesis of multiple myeloma. Blood. 2012;120(25):5002–13.22821765 10.1182/blood-2011-07-368142
15. Xin M Strategies to target the hedgehog signaling pathway for cancer therapy Med Res Rev 2018 38 3 870 913 10.1002/med.21482 29315702
Xin M, et al. Strategies to target the hedgehog signaling pathway for cancer therapy. Med Res Rev. 2018;38(3):870–913.29315702 10.1002/med.21482
16. Raleigh DR Reiter JF Misactivation of hedgehog signaling causes inherited and sporadic cancers J Clin Invest 2019 129 2 465 75 10.1172/JCI120850 30707108
Raleigh DR, Reiter JF. Misactivation of hedgehog signaling causes inherited and sporadic cancers. J Clin Invest. 2019;129(2):465–75.30707108 10.1172/JCI120850
17. Monkkonen T Lewis MT New paradigms for the hedgehog signaling network in mammary gland development and breast Cancer Biochim Biophys Acta Rev Cancer 2017 1868 1 315 32 10.1016/j.bbcan.2017.06.003 28624497
Monkkonen T, Lewis MT. New paradigms for the hedgehog signaling network in mammary gland development and breast Cancer. Biochim Biophys Acta Rev Cancer. 2017;1868(1):315–32.28624497 10.1016/j.bbcan.2017.06.003
18. Quail DF Joyce JA Microenvironmental regulation of tumor progression and metastasis Nat Med 2013 19 11 1423 37 10.1038/nm.3394 24202395
Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–37.24202395 10.1038/nm.3394
19. Cha YJ, Koo JS. Role of Tumor-Associated myeloid cells in breast Cancer. Cells, 2020. 9(8).
20. Williams CB Yeh ES Soloff AC Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy NPJ Breast Cancer 2016 2 15025 10.1038/npjbcancer.2015.25 26998515
Williams CB, Yeh ES, Soloff AC. Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy. NPJ Breast Cancer. 2016;2:15025.26998515 10.1038/npjbcancer.2015.25
21. Hanna A Inhibition of hedgehog signaling reprograms the dysfunctional immune microenvironment in breast cancer Oncoimmunology 2019 8 3 1548241 10.1080/2162402X.2018.1548241 30723576
Hanna A, et al. Inhibition of hedgehog signaling reprograms the dysfunctional immune microenvironment in breast cancer. Oncoimmunology. 2019;8(3):1548241.30723576 10.1080/2162402X.2018.1548241
22. Petty AJ Hedgehog signaling promotes tumor-associated macrophage polarization to suppress intratumoral CD8 + T cell recruitment J Clin Invest 2019 129 12 5151 62 10.1172/JCI128644 31638600
Petty AJ, et al. Hedgehog signaling promotes tumor-associated macrophage polarization to suppress intratumoral CD8 + T cell recruitment. J Clin Invest. 2019;129(12):5151–62.31638600 10.1172/JCI128644
23. Zhang D BMI1 regulates multiple myeloma-associated macrophage’s pro-myeloma functions Cell Death Dis 2021 12 5 495 10.1038/s41419-021-03748-y 33993198
Zhang D, et al. BMI1 regulates multiple myeloma-associated macrophage’s pro-myeloma functions. Cell Death Dis. 2021;12(5):495.33993198 10.1038/s41419-021-03748-y
24. Petty AJ et al. Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8 + T cell function. JCI Insight, 2021. 6(6).
25. Galon J Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 2006 313 5795 1960 4 10.1126/science.1129139 17008531
Galon J, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–4.17008531 10.1126/science.1129139
26. Ostroumov D CD4 and CD8 T lymphocyte interplay in controlling tumor growth Cell Mol Life Sci 2018 75 4 689 713 10.1007/s00018-017-2686-7 29032503
Ostroumov D, et al. CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cell Mol Life Sci. 2018;75(4):689–713.29032503 10.1007/s00018-017-2686-7
27. Rowbotham NJ A novel role for hedgehog in T-cell receptor signaling: implications for development and immunity Cell Cycle 2007 6 17 2138 42 10.4161/cc.6.17.4644 17786048
Rowbotham NJ, et al. A novel role for hedgehog in T-cell receptor signaling: implications for development and immunity. Cell Cycle. 2007;6(17):2138–42.17786048 10.4161/cc.6.17.4644
28. Mengrelis K Sonic hedgehog is a determinant of gammadelta T-Cell differentiation in the Thymus Front Immunol 2019 10 1629 10.3389/fimmu.2019.01629 31379834
Mengrelis K, et al. Sonic hedgehog is a determinant of gammadelta T-Cell differentiation in the Thymus. Front Immunol. 2019;10:1629.31379834 10.3389/fimmu.2019.01629
29. Holla S Mycobacteria-responsive sonic hedgehog signaling mediates programmed death-ligand 1- and prostaglandin E2-induced regulatory T cell expansion Sci Rep 2016 6 24193 10.1038/srep24193 27080341
Holla S, et al. Mycobacteria-responsive sonic hedgehog signaling mediates programmed death-ligand 1- and prostaglandin E2-induced regulatory T cell expansion. Sci Rep. 2016;6:24193.27080341 10.1038/srep24193
30. Rowbotham NJ Activation of the hedgehog signaling pathway in T-lineage cells inhibits TCR repertoire selection in the thymus and peripheral T-cell activation Blood 2007 109 9 3757 66 10.1182/blood-2006-07-037655 17227833
Rowbotham NJ, et al. Activation of the hedgehog signaling pathway in T-lineage cells inhibits TCR repertoire selection in the thymus and peripheral T-cell activation. Blood. 2007;109(9):3757–66.17227833 10.1182/blood-2006-07-037655
31. Koh V Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids Cancer Lett 2021 518 59 71 10.1016/j.canlet.2021.06.007 34126195
Koh V, et al. Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids. Cancer Lett. 2021;518:59–71.34126195 10.1016/j.canlet.2021.06.007
32. Zerdes I Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations Oncogene 2018 37 34 4639 61 10.1038/s41388-018-0303-3 29765155
Zerdes I, et al. Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. Oncogene. 2018;37(34):4639–61.29765155 10.1038/s41388-018-0303-3
33. Seif F Breast cancer tumor microenvironment affects Treg/IL-17-producing Treg/Th17 cell axis: Molecular and therapeutic perspectives Mol Ther Oncolytics 2023 28 132 57 10.1016/j.omto.2023.01.001 36816749
Seif F, et al. Breast cancer tumor microenvironment affects Treg/IL-17-producing Treg/Th17 cell axis: Molecular and therapeutic perspectives. Mol Ther Oncolytics. 2023;28:132–57.36816749 10.1016/j.omto.2023.01.001
34. Hinshaw DC Hedgehog signaling regulates Treg to Th17 Conversion through metabolic rewiring in breast Cancer Cancer Immunol Res 2023 11 5 687 702 10.1158/2326-6066.CIR-22-0426 37058110
Hinshaw DC, et al. Hedgehog signaling regulates Treg to Th17 Conversion through metabolic rewiring in breast Cancer. Cancer Immunol Res. 2023;11(5):687–702.37058110 10.1158/2326-6066.CIR-22-0426
35. Su X Comprehensive explorations of CCL28 in Lung Adenocarcinoma Immunotherapy and experimental validation J Inflamm Res 2023 16 1325 42 10.2147/JIR.S399193 37006812
Su X, et al. Comprehensive explorations of CCL28 in Lung Adenocarcinoma Immunotherapy and experimental validation. J Inflamm Res. 2023;16:1325–42.37006812 10.2147/JIR.S399193
36. Adolphe C Genetic and functional interaction network analysis reveals global enrichment of regulatory T cell genes influencing basal cell carcinoma susceptibility Genome Med 2021 13 1 19 10.1186/s13073-021-00827-9 33549134
Adolphe C, et al. Genetic and functional interaction network analysis reveals global enrichment of regulatory T cell genes influencing basal cell carcinoma susceptibility. Genome Med. 2021;13(1):19.33549134 10.1186/s13073-021-00827-9
37. Biffi G Tuveson DA Diversity and Biology of Cancer-Associated fibroblasts Physiol Rev 2021 101 1 147 76 10.1152/physrev.00048.2019 32466724
Biffi G, Tuveson DA. Diversity and Biology of Cancer-Associated fibroblasts. Physiol Rev. 2021;101(1):147–76.32466724 10.1152/physrev.00048.2019
38. Liu X Cancer-associated fibroblast infiltration in gastric cancer: the discrepancy in subtypes pathways and immunosuppression J Transl Med 2021 19 1 325 10.1186/s12967-021-03012-z 34332586
Liu X, et al. Cancer-associated fibroblast infiltration in gastric cancer: the discrepancy in subtypes pathways and immunosuppression. J Transl Med. 2021;19(1):325.34332586 10.1186/s12967-021-03012-z
39. Cazet AS Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer Nat Commun 2018 9 1 2897 10.1038/s41467-018-05220-6 30042390
Cazet AS, et al. Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. Nat Commun. 2018;9(1):2897.30042390 10.1038/s41467-018-05220-6
40. Liu J Cancer-associated fibroblasts promote hepatocellular carcinoma metastasis through chemokine-activated hedgehog and TGF-beta pathways Cancer Lett 2016 379 1 49 59 10.1016/j.canlet.2016.05.022 27216982
Liu J, et al. Cancer-associated fibroblasts promote hepatocellular carcinoma metastasis through chemokine-activated hedgehog and TGF-beta pathways. Cancer Lett. 2016;379(1):49–59.27216982 10.1016/j.canlet.2016.05.022
41. Ferreira Mendes JM et al. Effects of IGF-1 on Proliferation, Angiogenesis, Tumor Stem Cell Populations and Activation of AKT and Hedgehog Pathways in Oral Squamous Cell Carcinoma. Int J Mol Sci, 2020. 21(18).
42. Chong Y Galectin-1 from cancer-associated fibroblasts induces epithelial-mesenchymal transition through beta1 integrin-mediated upregulation of Gli1 in gastric cancer J Exp Clin Cancer Res 2016 35 1 175 10.1186/s13046-016-0449-1 27836001
Chong Y, et al. Galectin-1 from cancer-associated fibroblasts induces epithelial-mesenchymal transition through beta1 integrin-mediated upregulation of Gli1 in gastric cancer. J Exp Clin Cancer Res. 2016;35(1):175.27836001 10.1186/s13046-016-0449-1
43. Peiris-Pages M Sotgia F Lisanti MP Chemotherapy induces the cancer-associated fibroblast phenotype, activating paracrine Hedgehog-GLI signalling in breast cancer cells Oncotarget 2015 6 13 10728 45 10.18632/oncotarget.3828 25915429
Peiris-Pages M, Sotgia F, Lisanti MP. Chemotherapy induces the cancer-associated fibroblast phenotype, activating paracrine Hedgehog-GLI signalling in breast cancer cells. Oncotarget. 2015;6(13):10728–45.25915429 10.18632/oncotarget.3828
44. Steele NG Inhibition of hedgehog signaling alters fibroblast composition in pancreatic Cancer Clin Cancer Res 2021 27 7 2023 37 10.1158/1078-0432.CCR-20-3715 33495315
Steele NG, et al. Inhibition of hedgehog signaling alters fibroblast composition in pancreatic Cancer. Clin Cancer Res. 2021;27(7):2023–37.33495315 10.1158/1078-0432.CCR-20-3715
45. Kudo-Saito C Cancer-associated mesenchymal stem cells aggravate tumor progression Front Cell Dev Biol 2015 3 23 10.3389/fcell.2015.00023 25883937
Kudo-Saito C. Cancer-associated mesenchymal stem cells aggravate tumor progression. Front Cell Dev Biol. 2015;3:23.25883937 10.3389/fcell.2015.00023
46. Karnoub AE Mesenchymal stem cells within tumour stroma promote breast cancer metastasis Nature 2007 449 7162 557 63 10.1038/nature06188 17914389
Karnoub AE, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449(7162):557–63.17914389 10.1038/nature06188
47. Weiss ARR Dahlke MH Immunomodulation by Mesenchymal Stem cells (MSCs): mechanisms of action of living, apoptotic, and dead MSCs Front Immunol 2019 10 1191 10.3389/fimmu.2019.01191 31214172
Weiss ARR, Dahlke MH. Immunomodulation by Mesenchymal Stem cells (MSCs): mechanisms of action of living, apoptotic, and dead MSCs. Front Immunol. 2019;10:1191.31214172 10.3389/fimmu.2019.01191
48. Mao XD Research progress in breast cancer stem cells: characterization and future perspectives Am J Cancer Res 2022 12 7 3208 22 35968346
Mao XD, et al. Research progress in breast cancer stem cells: characterization and future perspectives. Am J Cancer Res. 2022;12(7):3208–22.35968346
49. Wu Q SCUBE2 mediates bone metastasis of luminal breast cancer by modulating immune-suppressive osteoblastic niches Cell Res 2023 33 6 464 78 10.1038/s41422-023-00810-6 37142671
Wu Q, et al. SCUBE2 mediates bone metastasis of luminal breast cancer by modulating immune-suppressive osteoblastic niches. Cell Res. 2023;33(6):464–78.37142671 10.1038/s41422-023-00810-6
50. Weidner N Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma N Engl J Med 1991 324 1 1 8 10.1056/NEJM199101033240101 1701519
Weidner N, et al. Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma. N Engl J Med. 1991;324(1):1–8.1701519 10.1056/NEJM199101033240101
51. Zhang M Anti-vascular endothelial growth factor therapy in breast cancer: molecular pathway, potential targets, and current treatment strategies Cancer Lett 2021 520 422 33 10.1016/j.canlet.2021.08.005 34389434
Zhang M, et al. Anti-vascular endothelial growth factor therapy in breast cancer: molecular pathway, potential targets, and current treatment strategies. Cancer Lett. 2021;520:422–33.34389434 10.1016/j.canlet.2021.08.005
52. Vokes SA Hedgehog signaling is essential for endothelial tube formation during vasculogenesis Development 2004 131 17 4371 80 10.1242/dev.01304 15294868
Vokes SA, et al. Hedgehog signaling is essential for endothelial tube formation during vasculogenesis. Development. 2004;131(17):4371–80.15294868 10.1242/dev.01304
53. Kanda S Sonic hedgehog induces capillary morphogenesis by endothelial cells through phosphoinositide 3-kinase J Biol Chem 2003 278 10 8244 9 10.1074/jbc.M210635200 12514186
Kanda S, et al. Sonic hedgehog induces capillary morphogenesis by endothelial cells through phosphoinositide 3-kinase. J Biol Chem. 2003;278(10):8244–9.12514186 10.1074/jbc.M210635200
54. Yamazaki M Sonic hedgehog derived from human pancreatic cancer cells augments angiogenic function of endothelial progenitor cells Cancer Sci 2008 99 6 1131 8 10.1111/j.1349-7006.2008.00795.x 18422746
Yamazaki M, et al. Sonic hedgehog derived from human pancreatic cancer cells augments angiogenic function of endothelial progenitor cells. Cancer Sci. 2008;99(6):1131–8.18422746 10.1111/j.1349-7006.2008.00795.x
55. Di Mauro C Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers Br J Cancer 2017 116 11 1425 35 10.1038/bjc.2017.116 28441382
Di Mauro C, et al. Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. Br J Cancer. 2017;116(11):1425–35.28441382 10.1038/bjc.2017.116
56. Harris LG Increased vascularity and spontaneous metastasis of breast cancer by hedgehog signaling mediated upregulation of cyr61 Oncogene 2012 31 28 3370 80 10.1038/onc.2011.496 22056874
Harris LG, et al. Increased vascularity and spontaneous metastasis of breast cancer by hedgehog signaling mediated upregulation of cyr61. Oncogene. 2012;31(28):3370–80.22056874 10.1038/onc.2011.496
57. Goel HL GLI1 regulates a novel neuropilin-2/alpha6beta1 integrin based autocrine pathway that contributes to breast cancer initiation EMBO Mol Med 2013 5 4 488 508 10.1002/emmm.201202078 23436775
Goel HL, et al. GLI1 regulates a novel neuropilin-2/alpha6beta1 integrin based autocrine pathway that contributes to breast cancer initiation. EMBO Mol Med. 2013;5(4):488–508.23436775 10.1002/emmm.201202078
58. Huang B Lang X Li X The role of IL-6/JAK2/STAT3 signaling pathway in cancers Front Oncol 2022 12 1023177 10.3389/fonc.2022.1023177 36591515
Huang B, Lang X, Li X. The role of IL-6/JAK2/STAT3 signaling pathway in cancers. Front Oncol. 2022;12:1023177.36591515 10.3389/fonc.2022.1023177
59. Wang H Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth Stem Cells 2009 27 10 2393 404 10.1002/stem.188 19658188
Wang H, et al. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells. 2009;27(10):2393–404.19658188 10.1002/stem.188
60. Conze D Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells Cancer Res 2001 61 24 8851 8 11751408
Conze D, et al. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res. 2001;61(24):8851–8.11751408
61. Benoy I Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients Clin Breast Cancer 2002 2 4 311 5 10.3816/CBC.2002.n.008 11899364
Benoy I, et al. Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer. 2002;2(4):311–5.11899364 10.3816/CBC.2002.n.008
62. Xu X M2 macrophage-derived IL6 mediates resistance of breast cancer cells to hedgehog inhibition Toxicol Appl Pharmacol 2019 364 77 82 10.1016/j.taap.2018.12.013 30578886
Xu X, et al. M2 macrophage-derived IL6 mediates resistance of breast cancer cells to hedgehog inhibition. Toxicol Appl Pharmacol. 2019;364:77–82.30578886 10.1016/j.taap.2018.12.013
63. Zhang Y Hypoxia in breast Cancer-scientific translation to therapeutic and diagnostic clinical applications Front Oncol 2021 11 652266 10.3389/fonc.2021.652266 33777815
Zhang Y, et al. Hypoxia in breast Cancer-scientific translation to therapeutic and diagnostic clinical applications. Front Oncol. 2021;11:652266.33777815 10.3389/fonc.2021.652266
64. Semenza GL Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy Trends Pharmacol Sci 2012 33 4 207 14 10.1016/j.tips.2012.01.005 22398146
Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012;33(4):207–14.22398146 10.1016/j.tips.2012.01.005
65. Liu ZJ Semenza GL Zhang HF Hypoxia-inducible factor 1 and breast cancer metastasis J Zhejiang Univ Sci B 2015 16 1 32 43 10.1631/jzus.B1400221 25559953
Liu ZJ, Semenza GL, Zhang HF. Hypoxia-inducible factor 1 and breast cancer metastasis. J Zhejiang Univ Sci B. 2015;16(1):32–43.25559953 10.1631/jzus.B1400221
66. Wang M Electrically activated polymetallic nanocrystals for long-term tumor suppression via oxygen-independent ROS generation and electro-immunotherapy J Control Release 2024 370 677 90 10.1016/j.jconrel.2024.05.017 38740093
Wang M, et al. Electrically activated polymetallic nanocrystals for long-term tumor suppression via oxygen-independent ROS generation and electro-immunotherapy. J Control Release. 2024;370:677–90.38740093 10.1016/j.jconrel.2024.05.017
67. Riobo-Del Galdo NA, Lara Montero A, Wertheimer EV. Role Hedgehog Signal Breast Cancer: Pathogenesis Ther Cells, 2019. 8(4).
68. Lama-Sherpa TD Quantitative longitudinal imaging reveals that inhibiting hedgehog activity alleviates the hypoxic Tumor Landscape Mol Cancer Res 2022 20 1 150 60 10.1158/1541-7786.MCR-21-0257 34593607
Lama-Sherpa TD, et al. Quantitative longitudinal imaging reveals that inhibiting hedgehog activity alleviates the hypoxic Tumor Landscape. Mol Cancer Res. 2022;20(1):150–60.34593607 10.1158/1541-7786.MCR-21-0257
69. Cho HK Tumor suppressor protein VHL inhibits hedgehog-gli activation through suppression of Gli1 nuclear localization FEBS Lett 2013 587 7 826 32 10.1016/j.febslet.2013.01.050 23395608
Cho HK, et al. Tumor suppressor protein VHL inhibits hedgehog-gli activation through suppression of Gli1 nuclear localization. FEBS Lett. 2013;587(7):826–32.23395608 10.1016/j.febslet.2013.01.050
70. Luczak MW Increased expression of HIF-1A and its implication in the hypoxia pathway in primary advanced uterine cervical carcinoma Oncol Rep 2011 26 5 1259 64 21887475
Luczak MW, et al. Increased expression of HIF-1A and its implication in the hypoxia pathway in primary advanced uterine cervical carcinoma. Oncol Rep. 2011;26(5):1259–64.21887475
71. Petrova V The hypoxic tumour microenvironment Oncogenesis 2018 7 1 10 10.1038/s41389-017-0011-9 29362402
Petrova V, et al. The hypoxic tumour microenvironment. Oncogenesis. 2018;7(1):10.29362402 10.1038/s41389-017-0011-9
72. Li Y Hypoxia-driven immunosuppressive metabolites in the Tumor Microenvironment: New approaches for Combinational Immunotherapy Front Immunol 2018 9 1591 10.3389/fimmu.2018.01591 30061885
Li Y, et al. Hypoxia-driven immunosuppressive metabolites in the Tumor Microenvironment: New approaches for Combinational Immunotherapy. Front Immunol. 2018;9:1591.30061885 10.3389/fimmu.2018.01591
73. Noman MZ Hypoxia: a key player in antitumor immune response. A review in the theme: Cellular responses to Hypoxia Am J Physiol Cell Physiol 2015 309 9 C569 79 10.1152/ajpcell.00207.2015 26310815
Noman MZ, et al. Hypoxia: a key player in antitumor immune response. A review in the theme: Cellular responses to Hypoxia. Am J Physiol Cell Physiol. 2015;309(9):C569–79.26310815 10.1152/ajpcell.00207.2015
74. Doedens AL Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression Cancer Res 2010 70 19 7465 75 10.1158/0008-5472.CAN-10-1439 20841473
Doedens AL, et al. Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res. 2010;70(19):7465–75.20841473 10.1158/0008-5472.CAN-10-1439
75. Onishi H The hedgehog inhibitor cyclopamine impairs the benefits of immunotherapy with activated T and NK lymphocytes derived from patients with advanced cancer Cancer Immunol Immunother 2013 62 6 1029 39 10.1007/s00262-013-1419-5 23591983
Onishi H, et al. The hedgehog inhibitor cyclopamine impairs the benefits of immunotherapy with activated T and NK lymphocytes derived from patients with advanced cancer. Cancer Immunol Immunother. 2013;62(6):1029–39.23591983 10.1007/s00262-013-1419-5
76. Liu B Wei C Hypoxia induces overexpression of CCL28 to Recruit Treg Cells to Enhance Angiogenesis in Lung Adenocarcinoma J Environ Pathol Toxicol Oncol 2021 40 1 65 74 10.1615/JEnvironPatholToxicolOncol.2020035859 33639074
Liu B, Wei C. Hypoxia induces overexpression of CCL28 to Recruit Treg Cells to Enhance Angiogenesis in Lung Adenocarcinoma. J Environ Pathol Toxicol Oncol. 2021;40(1):65–74.33639074 10.1615/JEnvironPatholToxicolOncol.2020035859
77. Westendorf AM Hypoxia enhances immunosuppression by inhibiting CD4 + effector T cell function and promoting Treg Activity Cell Physiol Biochem 2017 41 4 1271 84 10.1159/000464429 28278498
Westendorf AM, et al. Hypoxia enhances immunosuppression by inhibiting CD4 + effector T cell function and promoting Treg Activity. Cell Physiol Biochem. 2017;41(4):1271–84.28278498 10.1159/000464429
78. Chen Z Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions Signal Transduct Target Ther 2023 8 1 70 10.1038/s41392-023-01332-8 36797231
Chen Z, et al. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023;8(1):70.36797231 10.1038/s41392-023-01332-8
79. Merchant JL Ding L Hedgehog signaling links chronic inflammation to gastric Cancer precursor lesions Cell Mol Gastroenterol Hepatol 2017 3 2 201 10 10.1016/j.jcmgh.2017.01.004 28275687
Merchant JL, Ding L. Hedgehog signaling links chronic inflammation to gastric Cancer precursor lesions. Cell Mol Gastroenterol Hepatol. 2017;3(2):201–10.28275687 10.1016/j.jcmgh.2017.01.004
80. Boedtkjer E Pedersen SF The acidic Tumor Microenvironment as a driver of Cancer Annu Rev Physiol 2020 82 103 26 10.1146/annurev-physiol-021119-034627 31730395
Boedtkjer E, Pedersen SF. The acidic Tumor Microenvironment as a driver of Cancer. Annu Rev Physiol. 2020;82:103–26.31730395 10.1146/annurev-physiol-021119-034627
81. McCarty MF Whitaker J Manipulating tumor acidification as a cancer treatment strategy Altern Med Rev 2010 15 3 264 72 21155627
McCarty MF, Whitaker J. Manipulating tumor acidification as a cancer treatment strategy. Altern Med Rev. 2010;15(3):264–72.21155627
82. Estrella V Acidity generated by the tumor microenvironment drives local invasion Cancer Res 2013 73 5 1524 35 10.1158/0008-5472.CAN-12-2796 23288510
Estrella V, et al. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 2013;73(5):1524–35.23288510 10.1158/0008-5472.CAN-12-2796
83. Zhang F Imaging of Carbonic Anhydrase Level in Epilepsy with an environment-sensitive fluorescent probe Anal Chem 2023 95 40 14833 41 10.1021/acs.analchem.3c01368 37747928
Zhang F, et al. Imaging of Carbonic Anhydrase Level in Epilepsy with an environment-sensitive fluorescent probe. Anal Chem. 2023;95(40):14833–41.37747928 10.1021/acs.analchem.3c01368
84. Lee S Carbonic anhydrases reduce the acidity of the tumor microenvironment, promote immune infiltration, decelerate tumor growth, and improve survival in ErbB2/HER2-enriched breast cancer Breast Cancer Res 2023 25 1 46 10.1186/s13058-023-01644-1 37098526
Lee S, et al. Carbonic anhydrases reduce the acidity of the tumor microenvironment, promote immune infiltration, decelerate tumor growth, and improve survival in ErbB2/HER2-enriched breast cancer. Breast Cancer Res. 2023;25(1):46.37098526 10.1186/s13058-023-01644-1
85. Guerrini G Inhibition of smoothened in breast cancer cells reduces CAXII expression and cell migration J Cell Physiol 2018 233 12 9799 811 10.1002/jcp.26947 30132883
Guerrini G, et al. Inhibition of smoothened in breast cancer cells reduces CAXII expression and cell migration. J Cell Physiol. 2018;233(12):9799–811.30132883 10.1002/jcp.26947
86. Korkaya H Wicha MS HER-2, notch, and breast cancer stem cells: targeting an axis of evil Clin Cancer Res 2009 15 6 1845 7 10.1158/1078-0432.CCR-08-3087 19276254
Korkaya H, Wicha MS. HER-2, notch, and breast cancer stem cells: targeting an axis of evil. Clin Cancer Res. 2009;15(6):1845–7.19276254 10.1158/1078-0432.CCR-08-3087
87. Dontu G Role of notch signaling in cell-fate determination of human mammary stem/progenitor cells Breast Cancer Res 2004 6 6 R605 15 10.1186/bcr920 15535842
Dontu G, et al. Role of notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 2004;6(6):R605–15.15535842 10.1186/bcr920
88. Harrison H Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor Cancer Res 2010 70 2 709 18 10.1158/0008-5472.CAN-09-1681 20068161
Harrison H, et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res. 2010;70(2):709–18.20068161 10.1158/0008-5472.CAN-09-1681
89. Kasper M Selective modulation of Hedgehog/GLI target gene expression by epidermal growth factor signaling in human keratinocytes Mol Cell Biol 2006 26 16 6283 98 10.1128/MCB.02317-05 16880536
Kasper M, et al. Selective modulation of Hedgehog/GLI target gene expression by epidermal growth factor signaling in human keratinocytes. Mol Cell Biol. 2006;26(16):6283–98.16880536 10.1128/MCB.02317-05
90. Zhao X Telomerase-immortalized human mammary stem/progenitor cells with ability to self-renew and differentiate Proc Natl Acad Sci U S A 2010 107 32 14146 51 10.1073/pnas.1009030107 20660721
Zhao X, et al. Telomerase-immortalized human mammary stem/progenitor cells with ability to self-renew and differentiate. Proc Natl Acad Sci U S A. 2010;107(32):14146–51.20660721 10.1073/pnas.1009030107
91. Katoh M Networking of WNT, FGF, notch, BMP, and hedgehog signaling pathways during carcinogenesis Stem Cell Rev 2007 3 1 30 8 10.1007/s12015-007-0006-6 17873379
Katoh M. Networking of WNT, FGF, notch, BMP, and hedgehog signaling pathways during carcinogenesis. Stem Cell Rev. 2007;3(1):30–8.17873379 10.1007/s12015-007-0006-6
92. Ingram WJ Sonic hedgehog regulates Hes1 through a novel mechanism that is independent of canonical notch pathway signalling Oncogene 2008 27 10 1489 500 10.1038/sj.onc.1210767 17873912
Ingram WJ, et al. Sonic hedgehog regulates Hes1 through a novel mechanism that is independent of canonical notch pathway signalling. Oncogene. 2008;27(10):1489–500.17873912 10.1038/sj.onc.1210767
93. Schreck KC The notch target Hes1 directly modulates Gli1 expression and hedgehog signaling: a potential mechanism of therapeutic resistance Clin Cancer Res 2010 16 24 6060 70 10.1158/1078-0432.CCR-10-1624 21169257
Schreck KC, et al. The notch target Hes1 directly modulates Gli1 expression and hedgehog signaling: a potential mechanism of therapeutic resistance. Clin Cancer Res. 2010;16(24):6060–70.21169257 10.1158/1078-0432.CCR-10-1624
94. Clark AS Constitutive and inducible akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells Mol Cancer Ther 2002 1 9 707 17 12479367
Clark AS, et al. Constitutive and inducible akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther. 2002;1(9):707–17.12479367
95. Ramaswamy B Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway Cancer Res 2012 72 19 5048 59 10.1158/0008-5472.CAN-12-1248 22875023
Ramaswamy B, et al. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway. Cancer Res. 2012;72(19):5048–59.22875023 10.1158/0008-5472.CAN-12-1248
96. Xu J Up-Regulation of Glioma-Associated Oncogene Homolog 1 expression by serum starvation promotes cell survival in ER-Positive breast Cancer cells Cell Physiol Biochem 2015 36 5 1862 76 10.1159/000430156 26182949
Xu J, et al. Up-Regulation of Glioma-Associated Oncogene Homolog 1 expression by serum starvation promotes cell survival in ER-Positive breast Cancer cells. Cell Physiol Biochem. 2015;36(5):1862–76.26182949 10.1159/000430156
97. Filbin MG Coordinate activation of shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities Nat Med 2013 19 11 1518 23 10.1038/nm.3328 24076665
Filbin MG, et al. Coordinate activation of shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Nat Med. 2013;19(11):1518–23.24076665 10.1038/nm.3328
98. Wang Y The crosstalk of mTOR/S6K1 and hedgehog pathways Cancer Cell 2012 21 3 374 87 10.1016/j.ccr.2011.12.028 22439934
Wang Y, et al. The crosstalk of mTOR/S6K1 and hedgehog pathways. Cancer Cell. 2012;21(3):374–87.22439934 10.1016/j.ccr.2011.12.028
99. Kern D Hedgehog/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemia Oncogene 2015 34 42 5341 51 10.1038/onc.2014.450 25639866
Kern D, et al. Hedgehog/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemia. Oncogene. 2015;34(42):5341–51.25639866 10.1038/onc.2014.450
100. Pavitra E The role of NF-kappaB in breast cancer initiation, growth, metastasis, and resistance to chemotherapy Biomed Pharmacother 2023 163 114822 10.1016/j.biopha.2023.114822 37146418
Pavitra E, et al. The role of NF-kappaB in breast cancer initiation, growth, metastasis, and resistance to chemotherapy. Biomed Pharmacother. 2023;163:114822.37146418 10.1016/j.biopha.2023.114822
101. Guo Q NF-kappaB signaling in therapy resistance of breast cancer: mechanisms, approaches, and challenges Life Sci 2024 348 122684 10.1016/j.lfs.2024.122684 38710275
Guo Q, et al. NF-kappaB signaling in therapy resistance of breast cancer: mechanisms, approaches, and challenges. Life Sci. 2024;348:122684.38710275 10.1016/j.lfs.2024.122684
102. Cui W Expression and regulation mechanisms of Sonic hedgehog in breast cancer Cancer Sci 2010 101 4 927 33 10.1111/j.1349-7006.2010.01495.x 20180807
Cui W, et al. Expression and regulation mechanisms of Sonic hedgehog in breast cancer. Cancer Sci. 2010;101(4):927–33.20180807 10.1111/j.1349-7006.2010.01495.x
103. Duan ZH Cooperatively transcriptional and epigenetic regulation of sonic hedgehog overexpression drives malignant potential of breast cancer Cancer Sci 2015 106 8 1084 91 10.1111/cas.12697 25990213
Duan ZH, et al. Cooperatively transcriptional and epigenetic regulation of sonic hedgehog overexpression drives malignant potential of breast cancer. Cancer Sci. 2015;106(8):1084–91.25990213 10.1111/cas.12697
104. Colavito SA Significance of glioma-associated oncogene homolog 1 (GLI1) expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NFkappaB) pathway Breast Cancer Res 2014 16 5 444 10.1186/s13058-014-0444-4 25252859
Colavito SA, et al. Significance of glioma-associated oncogene homolog 1 (GLI1) expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NFkappaB) pathway. Breast Cancer Res. 2014;16(5):444.25252859 10.1186/s13058-014-0444-4
105. Song L Sinomenine reduces growth and metastasis of breast cancer cells and improves the survival of tumor-bearing mice through suppressing the SHh pathway Biomed Pharmacother 2018 98 687 93 10.1016/j.biopha.2017.12.065 29304494
Song L, et al. Sinomenine reduces growth and metastasis of breast cancer cells and improves the survival of tumor-bearing mice through suppressing the SHh pathway. Biomed Pharmacother. 2018;98:687–93.29304494 10.1016/j.biopha.2017.12.065
106. Che J Cyclopamine is a novel hedgehog signaling inhibitor with significant anti-proliferative, anti-invasive and anti-estrogenic potency in human breast cancer cells Oncol Lett 2013 5 4 1417 21 10.3892/ol.2013.1195 23599805
Che J, et al. Cyclopamine is a novel hedgehog signaling inhibitor with significant anti-proliferative, anti-invasive and anti-estrogenic potency in human breast cancer cells. Oncol Lett. 2013;5(4):1417–21.23599805 10.3892/ol.2013.1195
107. Shukla N TGF-beta at the crossroads of multiple prognosis in breast cancer, and beyond Life Sci 2022 310 121011 10.1016/j.lfs.2022.121011 36179816
Shukla N, et al. TGF-beta at the crossroads of multiple prognosis in breast cancer, and beyond. Life Sci. 2022;310:121011.36179816 10.1016/j.lfs.2022.121011
108. Khoshakhlagh M Therapeutic potential of pharmacological TGF-beta signaling pathway inhibitors in the pathogenesis of breast cancer Biochem Pharmacol 2019 164 17 22 10.1016/j.bcp.2019.03.031 30905655
Khoshakhlagh M, et al. Therapeutic potential of pharmacological TGF-beta signaling pathway inhibitors in the pathogenesis of breast cancer. Biochem Pharmacol. 2019;164:17–22.30905655 10.1016/j.bcp.2019.03.031
109. Moses H Barcellos-Hoff MH TGF-beta biology in mammary development and breast cancer Cold Spring Harb Perspect Biol 2011 3 1 a003277 10.1101/cshperspect.a003277 20810549
Moses H, Barcellos-Hoff MH. TGF-beta biology in mammary development and breast cancer. Cold Spring Harb Perspect Biol. 2011;3(1):a003277.20810549 10.1101/cshperspect.a003277
110. Johnson RW TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical hedgehog signaling Cancer Res 2011 71 3 822 31 10.1158/0008-5472.CAN-10-2993 21189326
Johnson RW, et al. TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical hedgehog signaling. Cancer Res. 2011;71(3):822–31.21189326 10.1158/0008-5472.CAN-10-2993
111. Dennler S Induction of sonic hedgehog mediators by transforming growth factor-beta: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo Cancer Res 2007 67 14 6981 6 10.1158/0008-5472.CAN-07-0491 17638910
Dennler S, et al. Induction of sonic hedgehog mediators by transforming growth factor-beta: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo. Cancer Res. 2007;67(14):6981–6.17638910 10.1158/0008-5472.CAN-07-0491
112. Javelaud D Pierrat MJ Mauviel A Crosstalk between TGF-beta and hedgehog signaling in cancer FEBS Lett 2012 586 14 2016 25 10.1016/j.febslet.2012.05.011 22609357
Javelaud D, Pierrat MJ, Mauviel A. Crosstalk between TGF-beta and hedgehog signaling in cancer. FEBS Lett. 2012;586(14):2016–25.22609357 10.1016/j.febslet.2012.05.011
113. Pratap J Runx2 transcriptional activation of Indian hedgehog and a downstream bone metastatic pathway in breast cancer cells Cancer Res 2008 68 19 7795 802 10.1158/0008-5472.CAN-08-1078 18829534
Pratap J, et al. Runx2 transcriptional activation of Indian hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res. 2008;68(19):7795–802.18829534 10.1158/0008-5472.CAN-08-1078
114. Rocca A et al. The predictive and prognostic role of RAS-RAF-MEK-ERK pathway alterations in breast Cancer: revision of the literature and comparison with the analysis of Cancer genomic datasets. Cancers (Basel), 2022. 14(21).
115. Giltnane JM Balko JM Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer Discov Med 2014 17 95 275 83 24882719
Giltnane JM, Balko JM. Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer. Discov Med. 2014;17(95):275–83.24882719
116. Lauth M Toftgard R Non-canonical activation of GLI transcription factors: implications for targeted anti-cancer therapy Cell Cycle 2007 6 20 2458 63 10.4161/cc.6.20.4808 17726373
Lauth M, Toftgard R. Non-canonical activation of GLI transcription factors: implications for targeted anti-cancer therapy. Cell Cycle. 2007;6(20):2458–63.17726373 10.4161/cc.6.20.4808
117. Ge X Sonic hedgehog stimulates glycolysis and proliferation of breast cancer cells: modulation of PFKFB3 activation Biochem Biophys Res Commun 2015 464 3 862 8 10.1016/j.bbrc.2015.07.052 26171876
Ge X, et al. Sonic hedgehog stimulates glycolysis and proliferation of breast cancer cells: modulation of PFKFB3 activation. Biochem Biophys Res Commun. 2015;464(3):862–8.26171876 10.1016/j.bbrc.2015.07.052
118. Thayer SP Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis Nature 2003 425 6960 851 6 10.1038/nature02009 14520413
Thayer SP, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature. 2003;425(6960):851–6.14520413 10.1038/nature02009
119. Seto M Regulation of the hedgehog signaling by the mitogen-activated protein kinase cascade in gastric cancer Mol Carcinog 2009 48 8 703 12 10.1002/mc.20516 19142899
Seto M, et al. Regulation of the hedgehog signaling by the mitogen-activated protein kinase cascade in gastric cancer. Mol Carcinog. 2009;48(8):703–12.19142899 10.1002/mc.20516
120. Rajurkar M The activity of gli transcription factors is essential for Kras-induced pancreatic tumorigenesis Proc Natl Acad Sci U S A 2012 109 17 E1038 47 10.1073/pnas.1114168109 22493246
Rajurkar M, et al. The activity of gli transcription factors is essential for Kras-induced pancreatic tumorigenesis. Proc Natl Acad Sci U S A. 2012;109(17):E1038–47.22493246 10.1073/pnas.1114168109
121. Ji Z Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells J Biol Chem 2007 282 19 14048 55 10.1074/jbc.M611089200 17353198
Ji Z, et al. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. J Biol Chem. 2007;282(19):14048–55.17353198 10.1074/jbc.M611089200
122. Morton JP Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis Proc Natl Acad Sci U S A 2007 104 12 5103 8 10.1073/pnas.0701158104 17372229
Morton JP, et al. Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proc Natl Acad Sci U S A. 2007;104(12):5103–8.17372229 10.1073/pnas.0701158104
123. Hashemi M Biological functions and molecular interactions of Wnt/beta-catenin in breast cancer: revisiting signaling networks Int J Biol Macromol 2023 232 123377 10.1016/j.ijbiomac.2023.123377 36702226
Hashemi M, et al. Biological functions and molecular interactions of Wnt/beta-catenin in breast cancer: revisiting signaling networks. Int J Biol Macromol. 2023;232:123377.36702226 10.1016/j.ijbiomac.2023.123377
124. Patel DK Scope of wnt signaling in the precise diagnosis and treatment of breast cancer Drug Discov Today 2023 28 7 103597 10.1016/j.drudis.2023.103597 37100166
Patel DK, et al. Scope of wnt signaling in the precise diagnosis and treatment of breast cancer. Drug Discov Today. 2023;28(7):103597.37100166 10.1016/j.drudis.2023.103597
125. Maeda O Enhancement of GLI1-transcriptional activity by beta-catenin in human cancer cells Oncol Rep 2006 16 1 91 6 16786128
Maeda O, et al. Enhancement of GLI1-transcriptional activity by beta-catenin in human cancer cells. Oncol Rep. 2006;16(1):91–6.16786128
126. Ulloa F Itasaki N Briscoe J Inhibitory Gli3 activity negatively regulates Wnt/beta-catenin signaling Curr Biol 2007 17 6 545 50 10.1016/j.cub.2007.01.062 17331723
Ulloa F, Itasaki N, Briscoe J. Inhibitory Gli3 activity negatively regulates Wnt/beta-catenin signaling. Curr Biol. 2007;17(6):545–50.17331723 10.1016/j.cub.2007.01.062
127. Arnold KM Pohlig RT Sims-Mourtada J Co-activation of hedgehog and wnt signaling pathways is associated with poor outcomes in triple negative breast cancer Oncol Lett 2017 14 5 5285 92 29142600
Arnold KM, Pohlig RT, Sims-Mourtada J. Co-activation of hedgehog and wnt signaling pathways is associated with poor outcomes in triple negative breast cancer. Oncol Lett. 2017;14(5):5285–92.29142600
128. Espinosa-Bustos C State of the art of smo antagonists for cancer therapy: advances in the target receptor and new ligand structures Future Med Chem 2019 11 6 617 38 10.4155/fmc-2018-0497 30912670
Espinosa-Bustos C, et al. State of the art of smo antagonists for cancer therapy: advances in the target receptor and new ligand structures. Future Med Chem. 2019;11(6):617–38.30912670 10.4155/fmc-2018-0497
129. Song L Targeting of sonic hedgehog-gli signaling: a potential therapeutic target for patients with breast cancer Oncol Lett 2016 12 2 1027 33 10.3892/ol.2016.4722 27446389
Song L, et al. Targeting of sonic hedgehog-gli signaling: a potential therapeutic target for patients with breast cancer. Oncol Lett. 2016;12(2):1027–33.27446389 10.3892/ol.2016.4722
130. Zhang X Cyclopamine inhibition of human breast cancer cell growth independent of smoothened (smo) Breast Cancer Res Treat 2009 115 3 505 21 10.1007/s10549-008-0093-3 18563554
Zhang X, et al. Cyclopamine inhibition of human breast cancer cell growth independent of smoothened (smo). Breast Cancer Res Treat. 2009;115(3):505–21.18563554 10.1007/s10549-008-0093-3
131. Liu S Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells Cancer Res 2006 66 12 6063 71 10.1158/0008-5472.CAN-06-0054 16778178
Liu S, et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 2006;66(12):6063–71.16778178 10.1158/0008-5472.CAN-06-0054
132. Di Magno L Digging a hole under hedgehog: downstream inhibition as an emerging anticancer strategy Biochim Biophys Acta 2015 1856 1 62 72 26080084
Di Magno L, et al. Digging a hole under hedgehog: downstream inhibition as an emerging anticancer strategy. Biochim Biophys Acta. 2015;1856(1):62–72.26080084
133. Mpekris F Sonic-hedgehog pathway inhibition normalizes desmoplastic tumor microenvironment to improve chemo- and nanotherapy J Control Release 2017 261 105 12 10.1016/j.jconrel.2017.06.022 28662901
Mpekris F, et al. Sonic-hedgehog pathway inhibition normalizes desmoplastic tumor microenvironment to improve chemo- and nanotherapy. J Control Release. 2017;261:105–12.28662901 10.1016/j.jconrel.2017.06.022
134. Pantziarka P Repurposing drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent Ecancermedicalscience 2015 9 521 10.3332/ecancer.2015.521 25932045
Pantziarka P, et al. Repurposing drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent. Ecancermedicalscience. 2015;9:521.25932045 10.3332/ecancer.2015.521
135. El-Sheridy NA Enhancing the in vitro and in vivo activity of itraconazole against breast cancer using miltefosine-modified lipid nanocapsules Drug Deliv 2021 28 1 906 19 10.1080/10717544.2021.1917728 33960245
El-Sheridy NA, et al. Enhancing the in vitro and in vivo activity of itraconazole against breast cancer using miltefosine-modified lipid nanocapsules. Drug Deliv. 2021;28(1):906–19.33960245 10.1080/10717544.2021.1917728
136. Okeke CI Co-delivery of Itraconazole and Docetaxel by Core/Shell Lipid Nanocells for systemic antiangiogenesis and Tumor Growth Inhibition J Biomed Nanotechnol 2017 13 11 1398 412 10.1166/jbn.2017.2428 31271127
Okeke CI, et al. Co-delivery of Itraconazole and Docetaxel by Core/Shell Lipid Nanocells for systemic antiangiogenesis and Tumor Growth Inhibition. J Biomed Nanotechnol. 2017;13(11):1398–412.31271127 10.1166/jbn.2017.2428
137. O’Toole SA Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer Cancer Res 2011 71 11 4002 14 10.1158/0008-5472.CAN-10-3738 21632555
O’Toole SA, et al. Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer. Cancer Res. 2011;71(11):4002–14.21632555 10.1158/0008-5472.CAN-10-3738
138. Resh MD Palmitoylation of hedgehog proteins by hedgehog acyltransferase: roles in signalling and disease Open Biol 2021 11 3 200414 10.1098/rsob.200414 33653085
Resh MD. Palmitoylation of hedgehog proteins by hedgehog acyltransferase: roles in signalling and disease. Open Biol. 2021;11(3):200414.33653085 10.1098/rsob.200414
139. Petrova E Inhibitors of hedgehog acyltransferase block Sonic hedgehog signaling Nat Chem Biol 2013 9 4 247 9 10.1038/nchembio.1184 23416332
Petrova E, et al. Inhibitors of hedgehog acyltransferase block Sonic hedgehog signaling. Nat Chem Biol. 2013;9(4):247–9.23416332 10.1038/nchembio.1184
140. Matevossian A Resh MD Hedgehog acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells Mol Cancer 2015 14 72 10.1186/s12943-015-0345-x 25889650
Matevossian A, Resh MD. Hedgehog acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells. Mol Cancer. 2015;14:72.25889650 10.1186/s12943-015-0345-x
141. Gonnissen A Isebaert S Haustermans K Targeting the hedgehog signaling pathway in cancer: beyond smoothened Oncotarget 2015 6 16 13899 913 10.18632/oncotarget.4224 26053182
Gonnissen A, Isebaert S, Haustermans K. Targeting the hedgehog signaling pathway in cancer: beyond smoothened. Oncotarget. 2015;6(16):13899–913.26053182 10.18632/oncotarget.4224
142. Valenti G Cancer Stem cells regulate Cancer-Associated fibroblasts via activation of hedgehog signaling in mammary gland tumors Cancer Res 2017 77 8 2134 47 10.1158/0008-5472.CAN-15-3490 28202523
Valenti G, et al. Cancer Stem cells regulate Cancer-Associated fibroblasts via activation of hedgehog signaling in mammary gland tumors. Cancer Res. 2017;77(8):2134–47.28202523 10.1158/0008-5472.CAN-15-3490
143. Neelakantan D EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells Nat Commun 2017 8 15773 10.1038/ncomms15773 28604738
Neelakantan D, et al. EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nat Commun. 2017;8:15773.28604738 10.1038/ncomms15773
144. Oladapo HO Pharmacological targeting of GLI1 inhibits proliferation, tumor emboli formation and in vivo tumor growth of inflammatory breast cancer cells Cancer Lett 2017 411 136 49 10.1016/j.canlet.2017.09.033 28965853
Oladapo HO, et al. Pharmacological targeting of GLI1 inhibits proliferation, tumor emboli formation and in vivo tumor growth of inflammatory breast cancer cells. Cancer Lett. 2017;411:136–49.28965853 10.1016/j.canlet.2017.09.033
145. Gan GN Jimeno A Emerging from their burrow: hedgehog pathway inhibitors for cancer Expert Opin Investig Drugs 2016 25 10 1153 66 10.1080/13543784.2016.1216973 27459882
Gan GN, Jimeno A. Emerging from their burrow: hedgehog pathway inhibitors for cancer. Expert Opin Investig Drugs. 2016;25(10):1153–66.27459882 10.1080/13543784.2016.1216973
146. Katoh M Genomic testing, tumor microenvironment and targeted therapy of hedgehog-related human cancers Clin Sci (Lond) 2019 133 8 953 70 10.1042/CS20180845 31036756
Katoh M. Genomic testing, tumor microenvironment and targeted therapy of hedgehog-related human cancers. Clin Sci (Lond). 2019;133(8):953–70.31036756 10.1042/CS20180845
147. Cosio T, Di Prete M, Campione E. Arsenic Trioxide, Itraconazole, All-Trans Retinoic Acid and Nicotinamide: a proof of Concept for Combined treatments with hedgehog inhibitors in Advanced basal cell carcinoma. Biomedicines, 2020. 8(6).
148. Munkacsy G, Santarpia L, Gyorffy B. Therapeutic potential of Tumor metabolic reprogramming in Triple-negative breast Cancer. Int J Mol Sci, 2023. 24(8).
149. Martinez-Outschoorn UE Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells Cancer Biol Ther 2011 12 10 924 38 10.4161/cbt.12.10.17780 22041887
Martinez-Outschoorn UE, et al. Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biol Ther. 2011;12(10):924–38.22041887 10.4161/cbt.12.10.17780
150. Zhai Y Self-activated arsenic manganite nanohybrids for visible and synergistic thermo/immuno-arsenotherapy J Control Release 2022 350 761 76 10.1016/j.jconrel.2022.08.054 36063961
Zhai Y, et al. Self-activated arsenic manganite nanohybrids for visible and synergistic thermo/immuno-arsenotherapy. J Control Release. 2022;350:761–76.36063961 10.1016/j.jconrel.2022.08.054
151. Chenna V A polymeric nanoparticle encapsulated small-molecule inhibitor of hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to smoothened antagonists Mol Cancer Ther 2012 11 1 165 73 10.1158/1535-7163.MCT-11-0341 22027695
Chenna V, et al. A polymeric nanoparticle encapsulated small-molecule inhibitor of hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to smoothened antagonists. Mol Cancer Ther. 2012;11(1):165–73.22027695 10.1158/1535-7163.MCT-11-0341
152. Hyman JM Small-molecule inhibitors reveal multiple strategies for hedgehog pathway blockade Proc Natl Acad Sci U S A 2009 106 33 14132 7 10.1073/pnas.0907134106 19666565
Hyman JM, et al. Small-molecule inhibitors reveal multiple strategies for hedgehog pathway blockade. Proc Natl Acad Sci U S A. 2009;106(33):14132–7.19666565 10.1073/pnas.0907134106
153. Jeng KS et al. Glioma-Associated Oncogene Homolog inhibitors have the potential of suppressing Cancer Stem cells of breast Cancer. Int J Mol Sci, 2018. 19(5).
154. Fan P Genistein decreases the breast cancer stem-like cell population through hedgehog pathway Stem Cell Res Ther 2013 4 6 146 10.1186/scrt357 24331293
Fan P, et al. Genistein decreases the breast cancer stem-like cell population through hedgehog pathway. Stem Cell Res Ther. 2013;4(6):146.24331293 10.1186/scrt357
155. Wu CH Targeting cancer stem cells in breast cancer: potential anticancer properties of 6-shogaol and pterostilbene J Agric Food Chem 2015 63 9 2432 41 10.1021/acs.jafc.5b00002 25686711
Wu CH, et al. Targeting cancer stem cells in breast cancer: potential anticancer properties of 6-shogaol and pterostilbene. J Agric Food Chem. 2015;63(9):2432–41.25686711 10.1021/acs.jafc.5b00002
156. Li M Curcumin inhibits the invasion and metastasis of triple negative breast cancer via Hedgehog/Gli1 signaling pathway J Ethnopharmacol 2022 283 114689 10.1016/j.jep.2021.114689 34592340
Li M, et al. Curcumin inhibits the invasion and metastasis of triple negative breast cancer via Hedgehog/Gli1 signaling pathway. J Ethnopharmacol. 2022;283:114689.34592340 10.1016/j.jep.2021.114689
157. Sun M Hedgehog pathway is involved in nitidine chloride induced inhibition of epithelial-mesenchymal transition and cancer stem cells-like properties in breast cancer cells Cell Biosci 2016 6 44 10.1186/s13578-016-0104-8 27313840
Sun M, et al. Hedgehog pathway is involved in nitidine chloride induced inhibition of epithelial-mesenchymal transition and cancer stem cells-like properties in breast cancer cells. Cell Biosci. 2016;6:44.27313840 10.1186/s13578-016-0104-8
158. Bose C Cananginone abrogates EMT in breast Cancer cells through hedgehog signaling Chem Biodivers 2022 19 5 e202100823 10.1002/cbdv.202100823 35298074
Bose C, et al. Cananginone abrogates EMT in breast Cancer cells through hedgehog signaling. Chem Biodivers. 2022;19(5):e202100823.35298074 10.1002/cbdv.202100823
159. Liu C Natural cordycepin induces apoptosis and suppresses metastasis in breast cancer cells by inhibiting the hedgehog pathway Food Funct 2020 11 3 2107 16 10.1039/C9FO02879J 32163051
Liu C, et al. Natural cordycepin induces apoptosis and suppresses metastasis in breast cancer cells by inhibiting the hedgehog pathway. Food Funct. 2020;11(3):2107–16.32163051 10.1039/C9FO02879J
160. Wu W et al. Cordycepin inhibits growth and metastasis formation of MDA-MB-231 xenografts in Nude mice by modulating the hedgehog pathway. Int J Mol Sci, 2022. 23(18).
161. Huang Y A systems Pharmacology Approach uncovers Wogonoside as an angiogenesis inhibitor of Triple-negative breast Cancer by targeting hedgehog signaling Cell Chem Biol 2019 26 8 1143 e11586 10.1016/j.chembiol.2019.05.004 31178408
Huang Y, et al. A systems Pharmacology Approach uncovers Wogonoside as an angiogenesis inhibitor of Triple-negative breast Cancer by targeting hedgehog signaling. Cell Chem Biol. 2019;26(8):1143–e11586.31178408 10.1016/j.chembiol.2019.05.004
162. Chen J Solasodine suppress MCF7 breast cancer stem-like cells via targeting Hedgehog/Gli1 Phytomedicine 2022 107 154448 10.1016/j.phymed.2022.154448 36116198
Chen J, et al. Solasodine suppress MCF7 breast cancer stem-like cells via targeting Hedgehog/Gli1. Phytomedicine. 2022;107:154448.36116198 10.1016/j.phymed.2022.154448
163. Chen YJ Small-molecule synthetic compound norcantharidin reverses multi-drug resistance by regulating sonic hedgehog signaling in human breast cancer cells PLoS ONE 2012 7 5 e37006 10.1371/journal.pone.0037006 22615870
Chen YJ, et al. Small-molecule synthetic compound norcantharidin reverses multi-drug resistance by regulating sonic hedgehog signaling in human breast cancer cells. PLoS ONE. 2012;7(5):e37006.22615870 10.1371/journal.pone.0037006
164. Ko YC et al. Physalin A, 13,14-Seco-16, 24-Cyclo-Steroid, inhibits stemness of breast Cancer cells by regulation of hedgehog Signaling Pathway and Yes-Associated protein 1 (YAP1). Int J Mol Sci, 2021. 22(16).
165. Wang X Huaier aqueous extract inhibits stem-like characteristics of MCF7 breast cancer cells via inactivation of hedgehog pathway Tumour Biol 2014 35 11 10805 13 10.1007/s13277-014-2390-2 25077927
Wang X, et al. Huaier aqueous extract inhibits stem-like characteristics of MCF7 breast cancer cells via inactivation of hedgehog pathway. Tumour Biol. 2014;35(11):10805–13.25077927 10.1007/s13277-014-2390-2
166. Sung H Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries CA Cancer J Clin 2021 71 3 209 49 10.3322/caac.21660 33538338
Sung H, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.33538338 10.3322/caac.21660
167. Tao Z Breast Cancer: epidemiology and etiology Cell Biochem Biophys 2015 72 2 333 8 10.1007/s12013-014-0459-6 25543329
Tao Z, et al. Breast Cancer: epidemiology and etiology. Cell Biochem Biophys. 2015;72(2):333–8.25543329 10.1007/s12013-014-0459-6
168. Korkaya H Liu S Wicha MS Breast cancer stem cells, cytokine networks, and the tumor microenvironment J Clin Invest 2011 121 10 3804 9 10.1172/JCI57099 21965337
Korkaya H, Liu S, Wicha MS. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest. 2011;121(10):3804–9.21965337 10.1172/JCI57099
169. Vera-Ramirez L Gene-expression profiles, tumor microenvironment, and cancer stem cells in breast cancer: latest advances towards an integrated approach Cancer Treat Rev 2010 36 6 477 84 10.1016/j.ctrv.2010.02.017 20299155
Vera-Ramirez L, et al. Gene-expression profiles, tumor microenvironment, and cancer stem cells in breast cancer: latest advances towards an integrated approach. Cancer Treat Rev. 2010;36(6):477–84.20299155 10.1016/j.ctrv.2010.02.017
170. LoRusso PM Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors Clin Cancer Res 2011 17 8 2502 11 10.1158/1078-0432.CCR-10-2745 21300762
LoRusso PM, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17(8):2502–11.21300762 10.1158/1078-0432.CCR-10-2745
171. Sekulic A Efficacy and safety of vismodegib in advanced basal-cell carcinoma N Engl J Med 2012 366 23 2171 9 10.1056/NEJMoa1113713 22670903
Sekulic A, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–9.22670903 10.1056/NEJMoa1113713
172. Atwood SX GLI activation by atypical protein kinase C iota/lambda regulates the growth of basal cell carcinomas Nature 2013 494 7438 484 8 10.1038/nature11889 23446420
Atwood SX, et al. GLI activation by atypical protein kinase C iota/lambda regulates the growth of basal cell carcinomas. Nature. 2013;494(7438):484–8.23446420 10.1038/nature11889
173. Yauch RL Smoothened mutation confers resistance to a hedgehog pathway inhibitor in medulloblastoma Science 2009 326 5952 572 4 10.1126/science.1179386 19726788
Yauch RL, et al. Smoothened mutation confers resistance to a hedgehog pathway inhibitor in medulloblastoma. Science. 2009;326(5952):572–4.19726788 10.1126/science.1179386
174. Buonamici S Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma Sci Transl Med 2010 2 51 51ra70 10.1126/scitranslmed.3001599 20881279
Buonamici S, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med. 2010;2(51):51ra70.20881279 10.1126/scitranslmed.3001599
175. Kim J Itraconazole and arsenic trioxide inhibit hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists Cancer Cell 2013 23 1 23 34 10.1016/j.ccr.2012.11.017 23291299
Kim J, et al. Itraconazole and arsenic trioxide inhibit hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell. 2013;23(1):23–34.23291299 10.1016/j.ccr.2012.11.017
176. Mukherjee S Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer Cancer Biol Ther 2006 5 6 674 83 10.4161/cbt.5.6.2906 16855373
Mukherjee S, et al. Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer. Cancer Biol Ther. 2006;5(6):674–83.16855373 10.4161/cbt.5.6.2906
177. Nocito MC et al. Antitumoral activities of Curcumin and recent advances to ImProve its oral bioavailability. Biomedicines, 2021. 9(10).
178. Zhao J Stromal modulation reverses primary resistance to Immune Checkpoint Blockade in Pancreatic Cancer ACS Nano 2018 12 10 9881 93 10.1021/acsnano.8b02481 30231203
Zhao J, et al. Stromal modulation reverses primary resistance to Immune Checkpoint Blockade in Pancreatic Cancer. ACS Nano. 2018;12(10):9881–93.30231203 10.1021/acsnano.8b02481
179. Khan S Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer Biomaterials 2019 208 83 97 10.1016/j.biomaterials.2019.04.005 30999154
Khan S, et al. Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer. Biomaterials. 2019;208:83–97.30999154 10.1016/j.biomaterials.2019.04.005
180. Tang JY Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome N Engl J Med 2012 366 23 2180 8 10.1056/NEJMoa1113538 22670904
Tang JY, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366(23):2180–8.22670904 10.1056/NEJMoa1113538
181. Ruiz-Borrego M A phase ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study Invest New Drugs 2019 37 1 98 108 10.1007/s10637-018-0614-9 29948356
Ruiz-Borrego M, et al. A phase ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study. Invest New Drugs. 2019;37(1):98–108.29948356 10.1007/s10637-018-0614-9
